

India Morning Roundup

October 14, 2026

Contents

• ICICI Life Insurance (IPRU) - Life Insurance | 2QFY27 Result Update - Protection and annuity aide NBV growth:

Key Points

- APE grew 15.6% YoY to Rs28.0bn in 2QFY27, while NBV grew 20.3% to Rs7.1bn and the NBV margin was 25.4%, up around 100bps YoY, led by a richer protection and annuity mix. APE was slightly ahead of consensus, NBV was in line, while NBV margin was a shade softer.
- Protection and annuity, the two focus areas, led the quarter. Protection APE was up 33.7% to a 20% share and annuity increased 65.5% to a 7% share.
- We maintain BUY with an unchanged TP of Rs660, implying 48% upside; solvency is strong at 229.9% with the IRDAI distribution consultation being the key overhang.


• Tata Elxsi Ltd. (TELX) - Information Technology | 2QFY27 Result Update - European Auto Slowdown Weighs on Outlook:

Key Points

- Tata Elxsi reported **revenue of Rs10,557mn** in Q2FY27, 0.6% above NBIE estimates and 1.3% above consensus estimates. Revenue grew **2.2% QoQ** and **7.8% YoY on a CC basis**.
- **EBIT margin at 19.7%** was 72bps below NBIE estimates but 85bps above consensus estimates. Despite wage hikes across the employee base, **EBITDA margin expanded by 70bps QoQ to 21.9%**, supported by operational efficiencies and cross-currency benefits.
- For FY27, **Tata Elxsi expects H2 to be better than H1**, supported by continued growth in transportation, media & communications, and healthcare & life sciences. Management remains optimistic about the long-term prospects of the healthcare vertical and expects growth to improve following the recent trough. However, the recovery remains dependent on deal ramp-ups and closures, while **softness in the European automotive market** continues to pose a risk to growth visibility.

- Corporate/Global/Local News
- Valuation Of Companies In Our Coverage Universe

Local Indices				
(Chg %)	Close	Daily	YTD	
BSE Sensex	73,034	1.5	(14.3)	
NSE Nifty	22,722	1.6	(13.0)	
Sectoral Indices				
(Chg %)	Close	Daily	YTD	
CNX Mid-Cap	59,459	1.1	(1.7)	
CNX Bank Nifty Index	55,481	1.0	(6.9)	
CNX Metal Index	12,088	1.1	8.2	
CNX FMCG Index	44,731	1.4	(19.4)	
CNX Infrastructure Index	8,579	0.9	(10.8)	
CNX Auto Index	25,392	1.2	(9.9)	
CNX Pharma Index	26,075	(0.0)	14.7	
CNX Energy Index	35,976	0.3	1.8	
CNX IT Index	29,830	5.2	(21.3)	
World Indices				
Dow Jones	51,670	(0.3)	7.5	
S & P 500	7,805	(0.0)	14.0	
FTSE 100	10,650	(0.1)	7.2	
Nasdaq	27,204	(0.2)	17.0	
Hang Seng	24,302	(0.2)	(5.2)	
Shanghai Comp	3,812	0.3	(4.0)	
Net Investment				
	14-Oct	1M	3M	
Fills (US\$m)	(336.5)	(102.1)	331.2	
MFs (US\$m)	929.1	115.5	139.1	
DII turnover (Rsm)	3,045.0	1,968.2	2,171.7	
Volume				
	14-Oct	US\$bn	Chg%	
Cash (NSE + BSE)	5.0	5.0	(5.9)	
F&O (net)	29.1	29.1	0.7	
Forex/Money Markets				
	14-Oct	1 D	1 M	3M
Rs/US\$	95.3	95.8	95.6	95.6
Rs/EUR	106.5	107.1	110.8	109.3
Rs/GBP	126.1	126.8	128.9	128.1
10 yr G-Sec	7.4	7.4	7.0	6.7
Call Money	5.2	5.1	4.7	4.9
Commodities & others				
	14-Oct	1 D	1 M	3 M
Gold (US\$/ounce)	4,159	4,161	4,300	4,053
Brent Crude (US\$)	107	106	101	81
Aluminium (US\$)	3,039	3,053	3,253	3,170
Copper (US\$/mt)	14,578	14,619	14,240	13,541



Please refer to the disclaimer towards the end of the document.

Corporate News

- Karur Vysya Bank has entered into an agreement with Zurich Kotak General Insurance Company for the distribution of general insurance products to cater the requirements of the Bank's customers.
- Shraddha Prime Projects has launched a 21-storey development 'Param Adarsh' located in Mulund West, Mumbai.
- Bajaj Healthcare has executed a Deed of Assignment with Spa Vet and Indosol Pure Technologies for the sale of an undertaking of the company situated at Dahej Industrial Area, GIDC, Bharuch, Gujarat.
- Crompton Greaves Consumer Electricals has introduced Crompton InstaNourish Pro Multi Purpose Kettle, designed to bring the 'Sear, Steam, Savour' experience to everyday cooking by combining multiple cooking options in one appliance.
- Puravankara has reported pre-sales of Rs 21360mn in Q2FY27, up 62% year-on-year (YoY) from Rs 13220mn in Q2FY26.
- Aequs has signed long-term supply agreements with Safran, a global leader in the aerospace industry for critical components.
- Karnataka Bank has launched 'Trade Konnect', a digital platform that enables customers to submit requests for import, export transactions and outward cross border remittances online, anytime, anywhere eliminating the need for physical branch visits.
- Lords Mark Industries has completed the acquisition of Radio Electric, the company behind the established 'Radiotone' brand, as part of its strategic expansion into specialised electrical manufacturing and engineering under its Lighting & Energy Division.
- Goodluck India's subsidiary- Goodluck Defence & Aerospace (GDAL), has emerged as the sole technically qualified bidder for the supply of specialised 155 mm HE M1A4 Ready-to-Fill Artillery Shells to Munitions India (MIL), following the audit and technical evaluation of various existing suppliers.
- Azad Engineering has been approved as a long-term source by Bharat Heavy Electricals (BHEL), a Maharatna Indian Public Sector Undertaking, and has been awarded a two-year long term rate contract for the supply of critical stationary and rotating airfoils (blades) for their heavy duty gas turbines.
- Tavexia Lifecare has secured approval to acquire a 60% controlling equity stake in Meyonex Pharmaceuticals.
- Juniper Green Energy has fully commissioned its 150 MW Wind Solar Hybrid Power Project under the Power Purchase Agreement with Gujarat Urja Vikas Nigam with the commissioning of final 5 MW wind turbine at the project site on October 12, 2026.
- Vikran Engineering's wholly-owned subsidiary -- NOPL Solar Projects (NOPL) has entered into a facility agreement with Indian Renewable Energy Development Agency (IREDA) for availing a rupee term loan facility aggregating up to Rs 29,411.9mn.

Global/Local News

- World stocks dipped on Tuesday as renewed AI concerns hit high-flying chipmakers, driving investors to the safety of government bonds as tech-heavy stock markets in Asia and the United States felt the brunt of the selloff.
- China's exports are expected to have expanded at a slightly faster pace in September, sustaining robust momentum despite pressure from some trading partners and remaining an economic growth driver.
- Anthropic said on Monday its experiments suggested small AI models may be months away from being capable enough to self-replicate on commercial internet-of-things (IoT) devices, such as smart ovens and off-brand Android TV boxes

ICICI Life Insurance (IPRU)

Life Insurance | 2QFY27 Result Update

BUY
CMP: Rs447 | Target Price (TP): Rs660 | Upside: 48%
October 13, 2026

Protection and annuity aid NBV growth

Key Points

- APE grew 15.6% YoY to Rs28.0bn in 2QFY27, while NBV grew 20.3% to Rs7.1bn and the NBV margin was 25.4%, up around 100bps YoY, led by a richer protection and annuity mix. APE was slightly ahead of consensus, NBV was in line, while NBV margin was a shade softer.
- Protection and annuity, the two focus areas, led the quarter. Protection APE was up 33.7% to a 20% share and annuity increased 65.5% to a 7% share.
- We maintain BUY with an unchanged TP of Rs660, implying 48% upside; solvency is strong at 229.9% with the IRDAI distribution consultation being the key overhang.

What we liked: NBV grew 20.3% YoY to Rs7.1bn in 2QFY27, outpacing APE growth of 15.6% to Rs28.0bn, as the mix shifted towards higher-margin protection and annuity. Protection APE grew 33.7% to a 20% share, with retail protection up 36.5%, while annuity grew 65.5% and group funds 51.5%. Partnership distribution and the group channel led growth, each up around 38-40%, on a highly diversified base where no single partner other than ICICI Bank exceeds 5% of APE. The balance sheet stayed strong, with solvency at 229.9% and embedded value up 12.2% YoY to Rs566.7bn. Cost discipline held, with the expense ratio excluding GST still improving, and quality metrics remained best-in-class, with a 99.3% claim settlement ratio and a 23% early-claim ratio, as the NBV margin expanded by around 100bps YoY to 25.4%.

What we did not like: The NBV margin eased by around 130bps QoQ to 25.4% from 26.7%, as the protection share of APE normalised to 20% from an unusually high 28% in 1Q, a reminder that margins swing with the quarterly mix. Headline growth was only moderate, with linked APE up 6.7% and softening late in the quarter on equity-market volatility; non-linked savings were broadly flat. The bank channel grew just 4%, with ICICI Bank steady at a Rs1.0-1.2bn monthly run rate. Agency growth remained modest at 6.2%. The reported cost ratio stayed elevated at 18.6% as the GST input tax credit remained unavailable, a drag set to persist for another quarter. The 25th-month persistency slipped to 76.2% from 77.0% and AUM fell 1.5% QoQ. Management also expects retail protection growth to taper in H2 from the 40-50% of recent quarters, while the IRDAI distribution and commission consultation remains an overhang, with credit life (about a third of protection) the most exposed.

We maintain our unchanged TP of Rs660 and a BUY rating: Our target price has remained unchanged as the roll-forward of the report date unwinds the discount to a fixed Mar-28E horizon, offsetting the lower implied multiple (1.6x vs 1.7x previously, see exhibit 2). We maintain our BUY rating on the stock. The share trades at 1.0x Mar-28E P/EV while offering a normalised ROEV of 13.0%.

Est Change	Maintain
TP Change	Maintain
Rating Change	Maintain

Company Data and Valuation Summary

Reuters	ICIR.BO
Bloomberg	IPRU IN Equity
Market Cap (Rsbn / US\$bn)	648.7 / 6.7
52 Wk H / L (Rs)	707 / 442
ADTV-3M (mn) (Rs / US\$)	887.3 / 9.3
Stock performance (%) 1M/6M/1yr	(5.2) / (18.2) / (24.7)
Nifty 50 performance (%) 1M/6M/1yr	(3.9) / (5.6) / (9.6)

Shareholding	3QFY25	4QFY25	1QFY26
Promoters	73.0	73.0	73.0
DII's	9.5	8.8	8.9
FII's	12.8	13.2	13.1
Others	4.8	5.0	5.1
Pro pledge	0.0	0.0	0.0

Financial and Valuation Summary

Particulars (Rsmn)	FY26	FY27E	FY28E	FY29E
APE	1,06,420	1,19,358	1,33,424	1,49,453
NBV	26,290	30,390	34,338	38,911
NBV margin	24.7%	25.5%	25.7%	26.0%
EV	5,29,879	6,02,537	6,79,149	7,68,397
ROEV	11%	14%	13%	13%
P/EV	1.2x	1.1x	1.0x	0.8x

Key Links - [2QFY27 presentation](#)

Please refer to the disclaimer towards the end of the document.

2QFY27 concall key takeaways

Product

- Total APE grew 15.6% YoY to Rs28.0bn in 2QFY27, with the mix moving further towards protection and annuity.
- Protection APE grew 33.7% to Rs5.6bn, lifting its share to 20.0% of APE from 17.3% a year earlier. Retail protection grew 36.5% to Rs2.3bn (8.3% of APE). Credit life remained about a third of protection, alongside retail protection and group term. Management expects retail protection growth to taper in H2 from the 40-50% of the past four quarters, as the base from last September's GST change normalises.
- Annuity APE grew 65.5% to Rs1.9bn, led by regular-premium deferred annuity and group funds growing 51.5% to Rs2.5bn. Annuity and non-par are expected to gain share if rates stay higher for longer.
- Linked APE grew 6.7% to Rs12.7bn (45.2% of APE), softening late in the quarter as equity-market volatility weighed on sentiment. Non-linked savings was broadly flat, down 0.6% to Rs5.3bn, recovering to near year-ago levels.
- Within non-linked savings the mix shifted towards non-par during the quarter to roughly 60:40 par to non-par.

Distribution

- On a 2Q APE basis the channel mix was bancassurance 27.5%, agency 22.8%, group 20.7%, partnership distribution 15.0%, and direct 14.1%.
- Partnership distribution and group led growth in the quarter, each up around 38-40% YoY. The partnership book is highly diversified, with over 1,600 partners and no single partner other than ICICI Bank above 5% of APE.
- Bancassurance grew about 4% YoY. ICICI Bank is roughly half of bancassurance, steady at a Rs1.0-1.2bn monthly run rate and focused on ULIP and protection, so growth is coming from the other bank partners; ICICI Bank is about 13-15% of total business.
- Agency grew 6.2% YoY, extending its turnaround from deep declines last year, helped by a micro-market approach and a shift to higher-quality, higher-margin products. Gross agent additions grew 23%, ahead of the market.
- Direct grew 9.4% YoY, with the focus on scaling online business and the NRI segment through GIFT City. The company has 52 bank tie-ups with access to 27,000-plus branches and over 1,600 non-bank partnerships.

Financial and qualitative factors

- NBV grew 20.3% YoY to Rs7.1bn in 2QFY27. The NBV margin was 25.4%, up around 100bps YoY but down around 130bps QoQ, as the protection share of APE normalised to 20% from an unusually high 28% in 1Q.
- Management framed margin as an outcome of NBV divided by APE and reiterated the focus on absolute NBV growth. The improvement was driven by the mix shift to protection, with yield-curve and opex gains largely passed to customers to drive demand.
- The reported cost ratio stayed elevated at about 18.6% as the GST input tax credit remained unavailable, a drag expected to persist for another quarter. Excluding GST, cost efficiency kept improving, with opex net of GST and stamp duty down at an 8% CAGR over three years.

- 13th-month persistency improved to 84.5% in September from 84.0% in June, while 25th-month eased to 76.2% from 77.0%. Management attributed the 25th-month slip to the same cohort challenge flowing through from the 13th month, with nothing noted as unusual.
- Solvency was strong at 229.9% and AUM stood at Rs3,289.6bn at quarter-end. Embedded value grew 12.2% YoY to Rs566.7bn, with the value of in-force up 12% to Rs423.9bn.
- Claim settlement remained industry-leading at 99.3% and the early-claim ratio was best-in-class at 23%, with sum assured market share at 11.5%.

Others

- The company has been renamed ICICI Life Insurance Limited, from ICICI Prudential Life Insurance, following Prudential's reclassification to investor from promoter; core strategy, operations, and governance are unchanged.
- Siddharth Mishra took over as MD and CEO from 14-Oct-26, succeeding Anup Bagchi, having previously led ICICI Bank's distribution channels. Strategy stays unchanged, centred on sustainable NBV growth with protection and annuity as priorities.
- On IRDAI's consultation paper recalibrating distribution economics and expense-of-management limits, the management sees it as being policyholder-friendly and positive for growth. It also views the company as being well-placed on cost ratios, and notes that the large renewal-commission allowance aligns distributor, customer, and company. It is too early to call, with no draft regulation yet.
- On credit life, the management stressed it is a societal need, especially for lower-income borrowers, and that premium is funded only with customer consent. The impact of a hypothetical 2% commission cap is too early to call.
- Risk-based capital and IFRS, both expected from FY28, are viewed as net positives after two quantitative impact studies, with no change to product strategy and little disruption for those who follow NBV and EV.

Exhibit 1: We make slight changes to our estimates

(Rsmn)	Revised estimate			Earlier estimate			% Revision		
	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E
APE	1,19,358	1,33,424	1,49,453	1,19,719	1,34,199	1,50,762	-0.3%	-0.6%	-0.9%
NBV	30,390	34,338	38,911	29,636	33,906	39,001	2.5%	1.3%	-0.2%
NBV margin	25.5%	25.7%	26.0%	24.8%	25.3%	25.9%	0.7%	0.5%	0.2%
EV	6,02,537	6,79,149	7,68,397	6,01,783	6,77,906	7,67,152	0.1%	0.2%	0.2%


Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 2: The average ROEV and implied multiple have reduced, while the target price is unchanged at Rs660, as the roll-forward offsets the softer multiple

	New	Old	Change
ROEV Mar-26A	10.5%	10.5%	0.0%
ROEV Mar-27E	13.7%	13.6%	0.1%
ROEV Mar-28E	12.7%	12.6%	0.1%
ROEV Mar-29E	13.1%	13.2%	0.0%
ROEV Mar-30E	13.1%	13.1%	0.0%
ROEV Mar-31E	13.1%	13.1%	-0.1%
ROEV Mar-32E	12.8%	13.1%	-0.3%
ROEV Mar-33E	12.6%	12.9%	-0.3%
Avg. ROEV 2029-33E	13.0%	13.1%	-0.1%
Sustainable growth	6%	6%	N/A
Cost of equity	10%	10%	N/A
Implied multiple	1.6x	1.7x	-0.1x
EV per share Mar-28E (Rs)	470	469	0.2%
Fair value per share (Rs)	763	793	-3.8%
Current fair value (Rs)	660	660	0.0%


Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 3: Annuity APE rose 65.5% YoY to Rs1.9bn from Rs1.2bn, the fastest of any segment




Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 4: Group and partnership distribution rose to 36% of APE from 30% YoY, as bancassurance slipped to 28% from 31%




Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 5: NBV grew 20% YoY on 16% APE growth, taking the NBV margin to 25.4% from 24.5%




Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 6: Protection APE rose 33.7% YoY, with retail up 36.5% and group up 31.7%




Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 7: Cost ratio rose to 18.6% from 17.5% YoY on lost GST input tax credit, ahead of IRDAI's proposed expense limits



Source: Company, Nirmal Bang Institutional Equities Research


Exhibit 8: 13th-month persistency eased to 84.5% from 85.3% YoY, while 37th-month persistency improved to 77.0% from 75.2%




Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 9: Solvency rose to 229.9% from 213.2% YoY, well above the 150% regulatory minimum

Exhibit 10: AUM rose 2.3% YoY to Rs3,290bn, though it fell 1.5% QoQ as linked funds took mark-to-market losses




Source: Company, Nirmal Bang Institutional Equities Research



Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 11: One-year forward P/EV



Source: Company, Nirmal Bang Institutional Equities Research

Financials

Exhibit 12: P&L summary

Y/E March (Rsmn)	Mar-26A	Mar-27E	Mar-28E	Mar-29E
Gross Premium income	5,31,246	5,76,913	6,42,194	7,20,445
Reinsurance outward	(17,890)	(19,428)	(21,626)	(24,261)
Net premium income	5,13,356	5,57,485	6,20,567	6,96,183
Investment income	1,19,609	2,25,032	2,38,032	2,55,509
Other income	3,886	2,000	2,000	2,001
Total income	6,36,851	7,84,516	8,60,599	9,53,693
Commission paid	51,811	54,807	62,935	70,604
Operating and other expenses	50,657	53,653	57,797	64,840
Provision for tax – policyholders	(2,530)	(4,759)	(5,034)	(5,404)
Claims/benefits paid (net)	4,71,951	5,13,452	5,71,552	6,41,196
Change in actuarial liability	46,843	1,50,782	1,55,789	1,63,578
Total expenses	6,18,733	7,67,934	8,43,039	9,34,814
Profit before tax	18,119	16,582	17,560	18,879
Tax	(2,040)	1,820	1,927	2,125
Profit after tax	16,079	18,402	19,487	21,004
- growth	36%	14%	6%	8%

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 13: Balance sheet summary

Y/E March (Rsmn)	Mar-26A	Mar-27E	Mar-28E	Mar-29E
Capital and Liabilities				
Shareholder's funds	1,36,312	1,54,555	1,71,658	1,90,277
Borrowings	25,950	25,950	25,950	25,950
Policy Liabilities	14,35,066	15,09,352	15,84,819	16,64,060
Provision for Linked Liabilities	14,52,744	15,18,117	15,94,023	16,73,724
Funds for discontinued policies	57,780	67,933	71,330	74,896
Funds for Future Appropriation	19,401	20,371	21,389	22,459
Total Liabilities and Shareholders' Funds	31,27,252	32,96,278	34,69,169	36,51,366
Assets				
Investments - Shareholders	1,57,276	1,65,140	1,76,699	1,89,068
Investments - Policyholders	14,12,995	14,83,645	16,00,924	17,27,881
Investments - Linked	15,10,524	15,86,050	16,65,352	17,48,620
Loans	30,062	37,578	46,972	58,715
Fixed Assets	7,110	7,537	7,763	7,996
Net current assets	9,285	16,329	(28,542)	(80,914)
Total assets	31,27,252	32,96,278	34,69,169	36,51,366

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 14: Operational metrics

Y/E March (Rsmn)	Mar-26A	Mar-27E	Mar-28E	Mar-29E
NBV	26,290	30,390	34,338	38,911
- growth	11%	16%	13%	13%
APE	1,06,420	1,19,358	1,33,424	1,49,453
- growth	2%	12%	12%	12%
NBV / APE margin	24.7%	25.5%	25.7%	26.0%
ROEV	11%	14%	13%	13%
NBV to opening EV	5%	6%	6%	6%
Embedded value	5,29,879	6,02,537	6,79,149	7,68,397

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 15: Per share data

Y/E March (Rs)	Mar-26A	Mar-27E	Mar-28E	Mar-29E
Book value	94.3	106.9	118.8	131.7
-growth	14%	13%	11%	11%
EV	367	416	469	531
-growth	11%	14%	13%	13%
EPS	11.1	12.7	13.5	14.5
-growth	36%	14%	6%	8%
DPS	1.7	1.7	1.7	1.7
-growth	94%	0%	0%	0%
-pay-out ratio	15%	13%	12%	11%

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 16: Group valuation metrics


Y/E March	Mar-26A	Mar-27E	Mar-28E	Mar-29E
P/B	4.7x	4.2x	3.8x	3.4x
- RoE	13%	13%	12%	12%
P/EV	1.2x	1.1x	1.0x	0.8x
- RoEV	11%	14%	13%	13%
P/E	40.2x	35.1x	33.2x	30.8x
Dividend yield	0.4%	0.4%	0.4%	0.4%

Source: Company, Nirmal Bang Institutional Equities Research

Rating track

Date	Rating	Market price (Rs)	Target price (Rs)
13 January 2026	Hold	685	657
14 January 2026	Hold	681	657
11 April 2026	BUY	547	650
15 April 2026	BUY	547	660
18 June 2026	BUY	504	660
09 July 2026	BUY	480	660
16 July 2026	BUY	525	660
25 September 2026	BUY	465	660
13 October 2026	BUY	447	660

Rating track graph



Tata Elxsi Ltd. (TELX)

Information Technology | 2QFY27 Result Update

HOLD

CMP: Rs3,427 | Target Price (TP): Rs3,825 | Upside: 11.6%

October 13, 2026

European Auto Slowdown Weighs on Outlook

Key Points

- Tata Elxsi reported **revenue of Rs10,557mn** in Q2FY27, 0.6% above NBIE estimates and 1.3% above consensus estimates. Revenue grew **2.2% QoQ and 7.8% YoY on a CC basis**.
- **EBIT margin at 19.7%** was 72bps below NBIE estimates but 85bps above consensus estimates. Despite wage hikes across the employee base, **EBITDA margin expanded by 70bps QoQ to 21.9%**, supported by operational efficiencies and cross-currency benefits.
- For FY27, **Tata Elxsi expects H2 to be better than H1**, supported by continued growth in transportation, media & communications, and healthcare & life sciences. Management remains optimistic about the long-term prospects of the healthcare vertical and expects growth to improve following the recent trough. However, the recovery remains dependent on deal ramp-ups and closures, while **softness in the European automotive market** continues to pose a risk to growth visibility.

AI-led deal wins and investments: Tata Elxsi secured multiple strategic deals during the quarter, including a **GenAI-powered multilingual virtual assistant for a global technology leader** and an **AI-powered enterprise knowledge graph platform for a global media and entertainment company**. The company also made an **early-stage strategic investment in KAVIA AI** to strengthen its capabilities in AI-driven software engineering. While these developments reinforce Tata Elxsi's positioning in AI-led product engineering, the revenue contribution and pace of monetisation remain key monitorables.

Outlook and valuation: Tata Elxsi delivered a sequential recovery in Q2FY27, with revenue growing 2.3% QoQ and 7.8% YoY on a CC basis, supported by broad-based growth across its key verticals. While the management expects H2FY27 to be better than H1, **we remain cautious about the sustainability of growth, given continued softness in European automotive demand and delays in deal closures**. Transportation accounts for over 55% of the SDS segment, making the recovery in automotive spending critical to the company's growth trajectory. Further, EBIT margin at 19.7% was supported partly by cross-currency benefits and the reversal of previous one-off costs. While the management expects gradual margin improvement through H2, the sustainability of operating leverage remains a key monitorable. We **reiterate our 'HOLD' rating on Tata Elxsi**, valuing it at an **unchanged 25x blended EPS of Rs153**, translating into a **target price of Rs3,825**.

Est Change	Downwards
TP Change	Downwards
Rating Change	Maintain

Company Data and Valuation Summary

Reuters	TTEX.BO
Bloomberg	TELX IN Equity
Market Cap (Rsbn / US\$bn)	213.5 / 2.2
52 Wk H / L (Rs)	5,950 / 2,996
ADTV-3M (mn) (Rs / US\$)	1,130.2 / 11.8
Stock performance (%) 1M/6M/1yr	1.3 / (22.3) / (36.0)
Nifty 50 performance (%) 1M/6M/1yr	(3.9) / (5.6) / (9.6)

Shareholding	3QFY26	4QFY26	1QFY27
Promoters	43.9	43.9	43.9
DII's	12.3	11.4	11.0
FII's	8.6	11.1	9.9
Others	35.2	33.6	35.2
Pro pledge	0.0	0.0	0.0

Financial and Valuation Summary

Particulars (Rsmn)	FY26	FY27E	FY28E	FY29E
Revenue (Rsmn)	37,575	42,322	45,473	49,167
YoY Growth %	0.8%	12.6%	7.4%	8.1%
Gross Margin	34.5%	34.5%	35.6%	36.3%
EBIT	7,531	8,467	10,018	11,139
% of sales	20.0%	20.0%	22.0%	22.7%
Adj. PAT	7,242	7,356	9,070	9,966
PAT Margin	19.3%	17.4%	19.9%	20.3%
YoY Growth %	-7.7%	1.6%	23.3%	9.9%
FDEPS (Rs)	116.2	118.1	145.6	160.0
ROE (%)	23.8	22.4	24.8	24.4
Post Tax ROCE (%)	18.9	19.1	22.1	22.1
Post Tax ROIC (%)	37.4	34.9	36.2	33.5
P/E (x)	29.5	29.0	23.5	21.4
EV/EBITDA	23.4	21.1	17.9	16.2
P/BV (x)	7.0	6.5	5.8	5.2

Source: Company, Bloomberg, Nirmal Bang Institutional Equities Research

Key Links:

Latest Result update: [1QFY27-Result-Update](#)

Please refer to the disclaimer towards the end of the document

Exhibit 1: Quarterly performance

Particulars (Rsmn)	1Q26	2Q26	3Q26	4Q26	1Q27	2Q27	3Q27	4Q27	FY26	FY27E	2Q27E	Var (%)
Net Sales (US\$mn)	104	104	107	107	109	110	112	114	423	445	112	(1.3)
QoQ Change (%)	-2.6	-0.2	2.4	0.7	1.1	1.7	1.5	2.0			3	
Net Sales	8,921	9,181	9,535	9,938	10,211	10,557	10,671	10,884	37,575	42,322	10,495	0.6
YoY Change (%)	-3.7	-3.9	1.5	9.4	14.5	15.0	11.9	9.5	0.8	12.6	14.3	
Software Expenses	5,957	6,112	6,154	6,377	6,704	6,935	6,989	7,075	24,599	27,703	6,822	1.7
% of Sales	66.8	66.6	64.5	64.2	65.7	65.7	65.5	65.0	65.5	65.0	65.0	
Gross Profit	2,964	3,069	3,381	3,561	3,507	3,621	3,681	3,809	14,619	3,673	3,673	(1.4)
Margin (%)	33.2	33.4	35.5	35.8	34.3	34.3	34.5	35.0	8.7	35.0	35.0	
Operating Expenses	1,097	1,136	1,158	1,115	1,347	1,307	1,280	1,197	4,506	5,132	1,259	3.8
% of Sales	12.3	12.4	12.1	11.2	13.2	12.4	12.0	11.0	12.1	12.0	12.0	
EBIT	1,624	1,699	1,994	2,213	1,937	2,078	2,123	2,329	7,531	8,467	2,141	(3.0)
YoY Change (%)	-27.9	-29.0	-9.6	21.0	19.3	22.3	6.5	5.2	-13.2	12.4	26.0	
Margin (%)	18.2	18.5	20.9	22.3	19.0	19.7	19.9	21.4	20.0	20.4	20.4	
Interest Expense	45.6	40.4	35.2	41.1	27	35.7	35.7	35.7	162	134	27.2	31.2
Other Income	385	489	460	506	415	349	349	349	1,840	1,462	415	(15.8)
PBT	1,963	2,147	1,463	2,678	2,325	2,391	2,437	2,643	9,208	9,795	2,528	(5.4)
Tax	520	599	374	474	619	688	543	589	1,967	2,439	632	8.8
ETR (%)	26.5	27.9	25.6	17.7	26.6	28.8	22.3	22.3	24.9	25.0	25.0	
Reported PAT	1,444	1,548	1,089	2,204	1,706	1,703	1,893	2,053	7,242	7,356	1,896	(10.2)
Adj. PAT	1,444	1,548	1,089	2,204	1,706	1,703	1,893	2,053	7,242	7,356	1,896	(10.2)
YoY Change (%)	-21.6	-32.5	-45.3	27.8	18.2	10.0	73.9	-6.8	-7.7	1.6	22.5	
Adj. EPS (Rs)	23.2	24.9	17.5	35.4	27.4	27.3	30.4	33.0	116.2	118.1	30.4	(10.2)

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 2: Change in our estimates

	Revised			Old			Change (%)		
	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E
Revenues (Rsmn)	42,322	45,473	49,167	42,437	46,947	49,167	(0.27)	(3.14)	-
EBIT (Rsmn)	8,467	10,018	11,139	9,166	10,816	11,139	(7.63)	(7.37)	-
EBIT margin (%)	20.0	22.0	22.7	21.6	23.0	22.7	-160bps	-100bps	0bps
FDEPS (Rs)	118	146	160	128	154	160	(8.06)	(5.50)	-
Revenues (US\$mn)	445	474	507	452	494	507	(1.49)	(4.15)	-
Revenue growth (US\$, %)	5.4	6.3	7.0	7.0	9.3	7.0	-160bps	-300bps	0bps

Source: Bloomberg, Nirmal Bang Institutional Equities Research

Exhibit 3: NBIE vs consensus estimates

	Consensus			NBIE			NBIE/Consensus		
	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E
Revenue (US\$mn)	435	475	528	445	474	507	102.5%	99.6%	96.0%
Revenue (Rsmn)	41,886	45,814	50,878	42,322	45,473	49,167	101.0%	99.3%	96.6%
EBIT (Rsmn)	8,365	10,833	11,665	8,467	10,018	11,139	101.2%	92.5%	95.5%
PAT (Rsmn)	7,416	8,806	10,076	7,242	7,356	9,070	97.6%	83.5%	90.0%
EPS (Rs)	118.9	141.6	161.6	118.1	145.6	160.0	99.3%	102.8%	99.0%
EBIT Margin (%)	20.0	23.6	22.9	20.0	22.0	22.7	0bps	-160bps	-30bps

Source: Company, Nirmal Bang Institutional Equities Research; Note: We have assumed USD/INR rate of Rs96, Rs97, and Rs98 for FY27E, FY28E, and FY29E, respectively

Highlights from the 2QFY27 analyst call

Demand environment

- Tata Elxsi reported revenue growth of 2.3% QoQ in constant currency (CC) terms to Rs10.557bn, with growth across all industry verticals. Management expects H2FY27 revenue growth to be better than H1FY27 on a YoY basis, supported by deal ramp-ups and healthy opportunities across media & communication and healthcare & life sciences.
- The automotive business continues to see growth from the US and India, while Europe remains soft due to delayed decision-making by OEMs. Existing European engagements are seeing slow ramp-ups and some project run-offs, although the management confirmed there have been no ramp-downs in ongoing projects.
- Management remains positive on the growth trajectory but highlighted the shorter working period and potential customer furloughs in Q3. The company does not provide formal revenue guidance. Enterprises continue to allocate budgets towards AI transformation, although spending is becoming more pragmatic and increasingly focused on demonstrable ROI.

Margins improve despite wage hikes

- EBITDA stood at Rs2.314bn, growing 7.1% QoQ and 19.7% YoY, while EBITDA margin improved by 70bps QoQ to 21.9%, despite the annual wage hikes implemented during the quarter.
- Management attributed 60–70bps of the sequential margin improvement to cross-currency benefits, with the remaining 10–20bps supported by operational leverage and the absence of most one-off costs incurred in the previous quarter. These benefits helped absorb the wage hike impact.
- Operational leverage is expected to continue through Q3 and Q4, as wage hikes for the year are completed. Management expects a gradual improvement in margins but did not provide a specific margin target for FY27.
- Utilization improved to 78%, with the management indicating further headroom towards historical peak levels of 81–82%. The company also plans to actively rebalance its employee pyramid over the next six months by progressively moving engagements from senior resources and technical experts to more junior employees.

Verticals, geographies, and service lines


- Transportation grew 2% QoQ in CC terms, supported by automotive OEM engagements and growth in the US and India. Europe remained soft, with large deals still awaiting closure; the management expects growth in the US and Asia to continue.
- Media and communication grew 3.4% QoQ in CC terms, driven by sustained ramp-ups across key engagements and AI-led deal wins. The company also secured a GenAI engagement with a global technology leader to develop a multilingual virtual assistant.
- Healthcare & life sciences grew 3.5% QoQ in CC terms, recovering from the weakness seen in the previous quarter. A notable win involved developing next-generation home dialysis systems for a global renal care leader. Management expects H2 performance to improve, supported by the deal pipeline and customer diversification.
- In transportation, Tata Elxsi won a multi-year engagement from a leading automotive OEM for a cloud-based telematics and connected-vehicle ecosystem. The company also entered a strategic collaboration with Sarla Aviation to support development of its Shunya eVTOL aircraft.
- Aerospace and defence are emerging growth opportunities, with new engagements secured from a global aerospace supplier for aircraft-system testing and validation. However, the business remains small, and these complex engagements typically take 2–3 quarters to ramp up.
- Growth in automotive continues to be driven by OEM customers, with the US and India supporting performance while Europe remains uncertain. Management noted that the contribution of other geographies to automotive growth is increasing, reducing the relative dependence on Europe.

- AI spending continues to compete with discretionary budgets, including R&D expenditure. However, the management sees enterprises becoming more selective and ROI-focused, with spending increasingly directed towards areas that can deliver meaningful cost savings and business impact.

Employee reduction and improved utilisation

- Total headcount reduced to 11,149 employees, resulting in a decrease by 187 employees. Utilization increased to 78%, with some further scope for improvement.
- The company intends to calibrate junior hiring and focus on employee-pyramid management over the next two to three quarters, while continuing to retain talent in high-demand areas such as engineering R&D. Management highlighted ongoing competition for specialised talent, including from global capability centres (GCCs).


Exhibit 4: US\$ revenue growth rate improves QoQ and YoY



Source: Company, Nirmal Bang Institutional Equities Research

Source: Company, Nirmal Bang Institutional Equities Research


Exhibit 5: Gross and EBITDA margin



Source: Company, Nirmal Bang Institutional Equities Research


Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 6: SG&A as a % of sales is down QoQ




Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 7: Effort mix is flat QoQ




Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 8: Attrition is high



Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 9: Net reduction for the seventh consecutive quarter



Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 10: Key metrics

	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27	2QFY27
P and L (Rsmn)										
Revenue	9,265	9,551	9,392	9,083	8,921	9,181	9,535	9,938	10,211	10,557
EBITDA	2,523	2,664	2,466	2,077	1,867	1,933	2,222	2,446	2,160	2,314
PAT	1,841	2,294	1,990	1,724	1,444	1,548	1,089	2,204	1,706	1,703
Vertical Mix (%)										
Transportation Business unit	52.8	55.7	55.0	53.4	55.8	54.7	56.6	56.3	55.3	55.3
Media and Communication	33.3	31.8	32.4	32.4	31.0	32.4	31.1	32.7	33.4	33.6
Life Science and Healthcare, others	13.9	12.5	12.6	14.2	13.2	12.9	12.3	11.0	11.3	11.1
Geographical Mix (%)										
Europe	42.2	42.7	40.4	37.9	39.5	38.7	42.1	43.1	42.2	40.7
Americas	33.7	30.3	30.9	30.6	30.1	31.6	32.0	28.9	31.7	33.2
India	17.6	18.8	19.4	22.4	19.8	19.0	16.7	16.8	16.4	16.6
ROW	6.5	8.3	9.3	9.1	10.5	10.7	9.3	11.1	9.7	9.5
Service Mix (%)										
Software Development & Services	97.0	97.1	97.5	96.3	97.3	96.9	97.2	97.1	96.9	97.0
System Integration and Support	3.0	2.9	2.5	3.7	2.7	3.1	2.8	2.9	3.1	3.0
Revenue Mix - IT Business (%)										
Offshore	72.8	74.7	74.2	74.1	73.1	73.9	73.1	75.0	74.1	74.0
Onsite	27.2	25.3	25.8	25.9	26.9	26.1	26.9	25.0	25.9	26.0
Clients Concentration (%)										
Top 5 Clients	47.2	45.1	44.8	45.6	44.7	44.2	49.4	49.6	49.2	48.9
Top 10 Clients	58.0	55.6	54.2	54.5	54.6	54.7	59.4	58.8	59.7	59.2
Revenue by Project type										
Fixed Price Project	50.9	50.5	51.9	50.7	51.9	56.3	54.4	58.9	57.8	56.9
Time & Material	49.1	49.5	48.1	49.3	48.1	43.7	45.6	41.1	42.2	43.1
Employees	13,142	12,793	12,878	12,414	12,127	11,951	11,594	11,540	11,336	11,149
Net Addition	(257)	(349)	85	(464)	(287)	(176)	(357)	(54)	(204)	(187)
TTM Attrition (%)	12.3	12.5	12.4	13.3	15.0	15.4	15.6	15.8	16.0	15.9


Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 11: QoQ and YoY growth on various parameters for Tata Elxsi

(in US\$)	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27	2QFY27
QoQ Growth (% US\$)										
By Geography (%)										
Europe	5.7	4.3	(7.8)	(9.6)	1.6	(2.2)	11.4	3.1	(1.0)	(2.0)
Americas	(5.5)	(7.3)	(0.7)	(4.6)	(4.1)	4.8	3.7	(9.1)	10.9	6.5
India	2.7	10.1	0.5	11.3	(13.9)	(4.2)	(10.0)	1.3	(1.3)	2.9
ROW	4.1	31.6	9.1	(5.7)	12.4	1.7	(11.0)	20.2	(11.6)	(0.4)
By Industry (%)										
Transportation Business unit	3.7	8.8	(3.8)	(6.5)	1.8	(2.1)	6.0	0.1	(0.7)	1.7
Media and Communication	0.0	(1.6)	(0.8)	(3.6)	(6.8)	4.3	(1.7)	5.8	3.3	2.3
Life Science and Healthcare	(6.5)	(7.3)	(1.8)	8.6	(9.4)	(2.4)	(2.3)	(10.0)	3.9	(0.1)
By Service Line (%)										
Software Development & Services	0.7	3.2	(2.2)	(4.8)	(1.5)	(0.6)	2.8	0.6	0.9	1.8
System Integration and Support	8.2	(0.3)	(16.0)	42.6	(28.9)	14.6	(7.5)	4.3	8.1	(1.6)
Revenues from Top Clients										
Top 5	3.1	(1.5)	(3.2)	(1.9)	(4.5)	(1.3)	14.5	1.1	0.3	1.0
Top 10	4.7	(1.2)	(5.0)	(3.1)	(2.4)	0.0	11.2	(0.3)	2.7	0.8
Onsite: Offshore Mix										
Offshore	(0.3)	5.8	(3.2)	(3.8)	(3.9)	0.9	1.3	3.3	(0.1)	1.5
Onsite	4.4	(4.1)	(0.7)	(3.3)	1.2	(3.1)	5.6	(6.4)	4.7	2.1
Project Type										
Fixed Price	7.3	2.3	0.1	(5.9)	(0.3)	8.3	(1.0)	9.0	(0.8)	0.1
Time & Materials	(4.9)	3.9	(5.4)	(1.2)	(4.9)	(9.3)	6.9	(9.3)	3.8	3.8
YoY Growth										
By Geography (%)										
Europe	20.2	14.7	0.8	(8.2)	(11.8)	(17.3)	0.1	14.1	11.2	11.5
Americas	(10.5)	(17.8)	(16.5)	(17.0)	(15.8)	(4.8)	(0.6)	(5.2)	9.6	11.4
India	10.6	30.3	19.6	26.5	6.1	(7.7)	(17.3)	(24.8)	(13.8)	(7.4)
ROW	31.0	82.0	64.9	41.1	52.3	17.7	(4.0)	22.4	(3.8)	(5.9)
By Industry (%)										
Transportation Business unit	25.9	29.6	19.6	1.5	(0.4)	(10.3)	(1.2)	5.8	3.2	7.2
Media and Communication	(10.6)	(11.0)	(13.4)	(5.8)	(12.2)	(7.0)	(7.8)	1.3	12.2	9.9
Life Science and Healthcare	(3.6)	(12.8)	(18.9)	(7.5)	(10.5)	(5.8)	(6.3)	(22.3)	(10.9)	(8.8)
By Service Line (%)										
Software Development & Services	20.6	21.3	14.6	(3.2)	(5.4)	(8.9)	(4.3)	1.2	3.7	6.1
System Integration and Support	14.4	15.4	(6.4)	29.1	(15.2)	(2.4)	7.5	(21.4)	19.5	2.6
Revenues from Top Clients										
Top 5	20.0	8.9	3.4	(3.6)	(10.7)	(10.5)	5.9	9.1	14.6	17.3
Top 10	19.4	12.3	4.4	(4.8)	(11.3)	(10.2)	5.2	8.2	13.8	14.7
Onsite: Offshore Mix										
Offshore	4.1	8.2	0.4	(1.8)	(5.3)	(9.7)	(5.4)	1.5	5.5	6.1
Onsite	14.8	5.4	3.1	(3.8)	(6.8)	(5.8)	0.1	(3.2)	0.2	5.6
Project Type										
Fixed Price	5.4	7.9	4.9	3.4	(3.9)	1.8	0.6	16.6	15.9	7.1
Time & Materials	8.3	7.0	(2.8)	(7.6)	(7.6)	(19.4)	(9.0)	(16.4)	(8.7)	4.5

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 12: 10-year P/E multiple




Source: Company, Bloomberg, Nirmal Bang Institutional Equities Research

Exhibit 13: 5-year P/E multiple



Source: Company, Bloomberg, Nirmal Bang Institutional Equities Research

Exhibit 14: P/E premium/(discount) to TCS



Source: Company, Bloomberg, Nirmal Bang Institutional Equities Research

Financials

Exhibit 15: Income statement

Y/E March (Rsmn)	FY25	FY26	FY27E	FY28E	FY29E
Average INR/USD	84.2	88.9	95.0	96.0	97.0
Net sales (US\$mn)	443	423	445	474	507
-Growth (%)	3.2%	-4.6%	5.4%	6.3%	7.0%
Net Sales	37,290	37,575	42,322	45,473	49,167
-Growth (%)	5.0%	0.8%	12.6%	7.4%	8.1%
Direct cost	22,862	24,599	27,703	29,270	31,341
Gross Profit	14,429	12,975	14,619	16,203	17,825
Gross Margin	38.7%	34.5%	34.5%	35.6%	36.3%
SGA Expenses	4699	4506	5132	5002	5408
% of sales	12.6%	12.0%	12.1%	11.0%	11.0%
EBITDA	9,729	8,469	9,487	11,201	12,417
% of sales	26.1%	22.5%	22.4%	24.6%	25.3%
Depreciation & Amortization	1049	938	1020	1182	1278
% of sales	2.8%	2.5%	2.4%	2.6%	2.6%
EBIT	8681	7531	8467	10018	11139
% of sales	23.3%	20.0%	20.0%	22.0%	22.7%
Other income (net)	1,793	1,840	1,462	1,462	1,462
Interest Cost	190	162	134	143	143
PBT	10,284	9,208	9,795	11,338	12,458
-PBT margin (%)	27.6%	24.5%	23.1%	24.9%	25.3%
Provision for tax	2,435	1,967	2,439	2,268	2,492
Effective tax rate (%)	23.7%	21.4%	24.9%	20.0%	20.0%
Net reported profit	7,849	7,242	7,356	9,070	9,966
-Growth (%)	-0.9%	-7.7%	1.6%	23.3%	9.9%
-Net profit margin (%)	21.0%	19.3%	17.4%	19.9%	20.3%

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 17: Balance sheet

Y/E March (Rsmn)	FY25	FY26	FY27E	FY28E	FY29E
Share capital	623	623	623	623	623
Reserves	27,977	29,790	32,162	35,936	40,295
Net worth	28,600	30,413	32,785	36,559	40,918
Long term debt	1,393	1,037	1,037	1,037	1,037
Short term debt	530	586	586	586	586
Total debt	1,923	1,623	1,623	1,623	1,623
Net debt	-14,178	-15,105	-13,527	-13,013	-12,805
Other non-current liabilities	568	605	605	605	605
Total Equity & Liabilities	35,857	39,625	42,111	45,978	50,458
Net Block	1,541	1,271	2,171	3,621	5,071
Right to use assets	1,567	1,272	1,372	1,472	1,572
Intangible and others	4,052	6,034	7,334	8,634	9,934
Other non-current assets	722	1,368	1,868	2,368	2,868
Inventories	0	0	0	0	0
Investments	37	41	141	241	291
Trade receivables	9,715	10,794	11,821	12,652	13,743
Cash & Cash Equivalents	16,064	16,686	15,009	14,395	14,137
Other current assets	2,159	2,160	2,396	2,596	2,844
Total current assets	27,975	29,681	29,367	29,884	31,014
Total current liabilities	5,297	7,570	7,684	7,777	7,899
Total Assets	35,857	39,625	42,111	45,978	50,458

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 16: Cash flow

Y/E March (Rsmn)	FY25	FY26	FY27E	FY28E	FY29E
PBT	10,284	9,208	9,795	11,338	12,458
Depreciation	(1,049)	(938)	(1,020)	(1,182)	(1,278)
Interest	-	-	-	-	-
Other adjustments	(1,793)	(1,840)	(1,462)	(1,462)	(1,462)
Change in Working capital	719	1,193	(1,149)	(938)	(1,216)
Tax paid	2,239	2,240	(2,439)	(2,268)	(2,492)
Operating cash flow	8,120	6,640	3,725	5,488	6,010
Capex	(188)	(477)	(1,280)	(1,668)	(1,572)
Free cash flow	7,932	6,162	2,445	3,820	4,438
Other investing activities	1,643	1,189	862	862	912
Investing cash flow	(3,083)	(725)	(419)	(806)	(660)
Issuance of share capital	365	(756)	-	-	-
Movement of Debt	(419)	-	-	-	-
Dividend paid (incl DDT)	(4,671)	(4,672)	(4,984)	(5,296)	(5,608)
Other financing activities	(393)	(319)	-	-	-
Financing cash flow	(4,986)	(5,348)	(4,984)	(5,296)	(5,608)
Net change in cash flow	51	567	(1,678)	(614)	(258)
Opening C&CE	13,571	16,064	16,686	15,009	14,395
Closing C&CE	16,064	16,686	15,009	14,395	14,137

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 18: Key ratios


Y/E March	FY25	FY26	FY27E	FY28E	FY29E
Per Share (Rsmn)					
FDEPS	126.0	116.2	118.1	145.6	160.0
Dividend Per Share	75.0	75.0	80.0	85.0	90.0
Book Value	459	488	526	587	657
Valuation ratios (x)					
P/Sales	5.7	5.7	5.0	4.7	4.3
EV/EBITDA	20.5	23.4	21.1	17.9	16.2
PER	27.2	29.5	29.0	23.5	21.4
P/BV	7.5	7.0	6.5	5.8	5.2
Return ratios (%)					
RoE	27.4	23.8	22.4	24.8	24.4
Post Tax RoCE	22.9	18.9	19.1	22.1	22.1
Pre Tax RoCE	30.0	24.1	25.5	27.6	27.6
Post Tax ROIC	44.4	37.4	34.9	36.2	33.5
Profitability ratios (%)					
Gross Margin	38.7	34.5	34.5	35.6	36.3
EBITDA Margin	26.1	22.5	22.4	24.6	25.3
PAT Margin	21.0	19.3	17.4	19.9	20.3
Liquidity ratios (%)					
Current Ratio	5.3	3.9	3.8	3.8	3.9
Quick Ratio	5.3	3.9	3.8	3.8	3.9
Solvency ratio (%)					
Net Debt/Equity	-0.5	-0.5	-0.4	-0.4	-0.3
Turnover Ratios					
Asset Turnover Ratio	1.0	0.9	1.0	1.0	1.0
Debtor Days	97	105	108	105	106

Source: Company, Nirmal Bang Institutional Equities Research.

Rating track

Date	Rating	Market price (Rs)	Target price (Rs)
24 May 2025	Hold	6,300	6,274
02 July 2025	Hold	6,310	6,119
11 July 2025	Sell	6,138	5,537
10 October 2025	Sell	5,573	5,186
14 January 2026	Hold	5,793	5,764
22 April 2026	Hold	4,651	4,837
15 July 2026	Hold	3,697	3,857
13 October 2026	Hold	3,427	3,825

Rating track graph



Valuation Of Companies In Our Coverage Universe

Auto - OEM

Yash Agrawal (yash.agrawal@nirmalbang.com)

Operational Metrics

company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Large Cap (M-cap >US\$5bn)																			
Bajaj Auto	10,318	12,901	Buy	29,767	5,87,325	7,17,952	8,22,916	1,20,166	1,43,164	1,67,631	98,330	1,15,325	1,33,500	351.5	420.1	486.4	18.4	18.1	16.5
Eicher Motors	7,163	9,123	Buy	20,644	2,34,076	2,73,079	3,12,833	57,851	67,946	77,364	55,707	63,856	73,186	203.2	232.9	266.9	15.6	15.6	14.6
Hero MotoCorp	4,998	6,850	Buy	10,500	4,68,301	5,57,962	6,27,256	68,708	71,564	92,404	53,872	56,335	71,662	269.4	281.7	358.3	15.7	16.0	15.3
Mahindra & Mahindra	2,864	4,537	Buy	37,394	14,77,654	16,87,846	19,45,403	2,24,898	2,22,796	2,90,838	1,57,372	1,57,362	2,06,093	126.6	126.5	165.7	14.7	13.7	14.4
Maruti Suzuki India	11,245	16,580	Buy	37,116	18,32,661	21,66,528	24,98,865	2,20,441	2,27,485	3,09,859	1,50,393	1,44,840	1,96,711	478.3	460.7	625.7	16.8	18.6	14.4
Hyundai Motor India	1,965	2,069	Hold	16,761	7,07,633	7,92,119	8,96,542	85,985	87,501	1,02,534	54,315	54,432	63,969	66.8	67.0	78.7	12.6	9.2	8.5
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Ashok Leyland	147	197	Buy	9,088	4,40,070	4,86,554	5,30,986	57,322	56,440	69,825	39,140	37,866	48,103	6.7	6.4	8.2	9.8	10.4	10.9
TVS Motor Co	4,012	4,291	Hold	20,008	4,72,703	5,77,872	6,62,685	60,794	74,068	86,429	36,566	45,913	53,072	77.0	96.6	111.7	18.4	19.2	20.5
Small Cap (M-cap <US\$1.5bn)																			
Ather Energy	1,495	1,873	Buy	6,226	36,718	57,024	82,372	(4,084)	(1,413)	106	(5,121)	(3,286)	(1,901)	(13.4)	(8.6)	(5.0)	49.8	NA	(39.1)

Valuation Metrics

company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	PIE (X)			EV/EBITDA (X)			PBV (X)			RoE (%)			RoCE (%)		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Large Cap (M-cap >US\$5bn)																			
Bajaj Auto	10,318	12,901	Buy	29,767	29.4	24.6	21.2	23.5	19.4	16.2	8.2	8.0	6.7	28.1	32.2	31.1	37.1	42.6	41.2
Eicher Motors	7,163	9,123	Buy	20,644	35.3	34.0	28.8	34.0	28.8	25.0	9.2	7.8	6.7	24.9	24.5	24.5	24.5	25.4	25.1
Hero MotoCorp	4,998	6,850	Buy	10,500	18.6	17.7	13.9	14.5	13.9	10.6	4.6	4.3	3.9	25.0	24.5	28.3	31.9	31.8	36.7
Mahindra & Mahindra	2,864	4,537	Buy	37,394	22.6	22.6	17.3	15.1	15.1	11.1	4.8	4.1	3.4	21.2	18.0	19.5	27.3	23.3	25.3
Maruti Suzuki India	11,245	16,580	Buy	37,116	23.5	24.4	18.0	16.0	15.4	11.1	3.4	3.1	2.7	14.3	12.6	15.1	18.4	16.4	19.6
Hyundai Motor India	1,965	2,069	Hold	16,761	29.4	29.3	25.0	17.5	17.2	14.6	8.0	6.7	5.6	29.9	24.8	24.5	28.8	24.1	24.0
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Ashok Leyland	147	197	Buy	9,088	22.1	22.9	18.0	14.8	14.9	11.8	6.6	6.1	5.4	31.8	27.7	31.7	37.6	34.1	39.9
TVS Motor Co	4,012	4,291	Hold	20,008	52.1	41.5	35.9	31.8	26.0	21.8	17.0	12.6	9.6	32.5	30.3	26.8	33.6	34.1	31.9
								EV/Sales (X)											
								FY26	FY27E	FY28E									
Small Cap (M-cap <US\$1.5bn)																			
Ather Energy	1,495	1,873	Buy	6,226	(111.7)	(174.1)	(301.0)	15.9	10.2	7.1	22.2	16.1	17.1	(19.9)	(9.3)	(5.7)	(12.6)	(5.9)	(2.9)

Auto - Ancillary

Yash Agrawal (yash.agrawal@nirmalbang.com)

Operational Metrics

Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Large Cap (M-cap >US\$5bn)																			
Balkrishna Industries	1,999	2,609	Buy	4,056	1,06,560	1,27,480	1,44,795	20,992	26,756	31,477	13,759	15,883	18,877	71.2	82.2	97.7	16.6	22.5	17.1
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Apollo Tyres	402	502	Hold	2,680	2,84,706	3,19,511	3,48,544	41,432	40,738	48,796	24,059	15,982	21,638	37.9	25.2	34.1	10.6	8.5	(5.2)
Small Cap (M-cap <US\$1.5bn)																			
Ceat	3,291	3,927	Hold	1,398	1,56,780	1,89,488	2,02,352	20,472	19,073	23,153	6,814	5,509	9,106	172.4	142.0	231.2	13.6	6.3	15.6
Sanseera Engineering	4,255	3,712	Hold	2,788	34,979	42,003	51,452	6,321	7,970	10,085	3,364	3,893	5,168	54.0	62.5	82.9	21.3	26.3	24.0
Suprajit Engineering	458	667	Buy	660	38,248	44,389	50,271	3,966	5,656	6,528	1,905	3,027	3,718	13.9	22.1	27.1	14.6	28.3	39.7
ASK Automotive Ltd	604	741	Buy	1,250	41,763	50,916	61,163	5,309	6,678	8,593	2,973	3,797	5,092	15.1	19.3	25.8	21.0	27.2	30.9

Valuation Metrics

Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	P/E (X)			EV/EBITDA (X)			PBV (X)			RoE (%)			RoCE (%)		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Large Cap (M-cap >US\$5bn)																			
Balkrishna Industries	1,999	2,609	Buy	4,056	28.1	24.3	20.5	20.3	15.9	13.6	3.5	3.2	2.8	12.5	13.0	13.7	11.4	13.4	14.7
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Apollo Tyres	402	502	Hold	2,680	10.6	16.0	11.8	6.5	6.7	5.6	1.5	1.4	1.3	14.4	8.9	10.9	13.5	11.6	14.0
Small Cap (M-cap <US\$1.5bn)																			
Ceat	3,291	3,927	Hold	1,398	19.1	23.2	14.2	7.9	8.5	7.0	2.6	2.5	2.2	14.5	10.5	15.8	16.8	11.7	14.7
Sanseera Engineering	4,255	3,712	Hold	2,788	78.8	68.1	51.3	42.1	33.4	26.4	8.6	7.6	6.6	11.5	11.9	13.8	14.3	14.7	17.1
Suprajit Engineering	458	667	Buy	660	33.0	20.8	16.9	17.0	11.9	10.3	4.4	3.8	3.2	13.3	18.3	19.1	16.3	19.8	21.2
ASK Automotive Ltd	604	741	Buy	1,250	40.0	31.3	23.4	23.6	18.8	14.6	9.1	7.3	5.7	22.7	23.3	24.5	20.7	23.1	26.1

Banking																			
Akshat Agrawal (akshat.agrawal@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	Net Interest Income (Rsmn)			Op Profit (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	NII	PPOP	PAT
Large Cap (M-cap >US\$5bn)																			
Axis Bank	1,268	1,490	Hold	41,463	5,60,480	6,50,025	7,91,248	4,28,168	5,22,116	6,38,739	2,44,567	3,18,979	3,95,642	78.8	102.6	127.2	18.8	22.1	27.2
Bandhan Bank	172	200	Hold	2,909	1,08,297	1,20,452	1,41,244	58,649	60,109	72,226	12,236	24,412	30,877	7.6	15.2	19.2	14.2	11.0	58.9
Bank of Baroda	238	325	Buy	12,944	4,76,825	5,42,694	6,36,744	3,22,590	3,57,955	4,32,835	2,00,211	1,92,526	2,53,082	38.7	37.2	48.9	15.6	15.8	12.4
HDFC Bank	714	1,020	Buy	1,15,573	12,86,860	14,67,101	17,40,206	11,85,583	12,36,661	14,90,509	7,46,713	8,20,684	9,96,976	48.6	53.3	64.7	16.3	12.1	15.5
ICICI Bank	1,360	1,820	Buy	1,02,525	8,80,752	10,36,137	12,33,286	7,15,989	8,39,628	10,09,826	5,01,466	5,94,767	7,08,593	70.2	83.0	98.8	18.3	18.9	18.9
IndusInd Bank	877	1,050	Hold	7,176	1,79,823	1,90,874	2,30,866	92,022	1,05,008	1,40,977	9,333	43,239	66,494	12.0	55.5	85.4	13.3	23.8	166.9
Kotak Mahindra Bank	439	475	Buy	45,847	3,00,101	3,35,671	3,95,240	2,20,669	2,55,265	3,02,317	1,40,077	1,67,997	1,92,533	14.1	16.9	19.4	14.8	17.0	17.2
Punjab National Bank	117	115	Hold	14,062	4,19,598	4,73,868	5,43,553	2,92,896	3,04,108	3,50,608	1,69,040	1,95,221	2,12,037	14.7	17.0	18.4	13.8	9.4	12.0
State Bank of India	957	1,275	Buy	92,739	17,31,205	20,03,183	23,14,726	11,84,220	13,91,164	16,14,253	8,00,320	8,78,973	10,21,042	87.6	95.2	110.6	15.6	16.8	13.0
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
AU Small Finance Bank	992	1,130	Hold	7,821	91,127	1,17,763	1,44,620	50,888	66,408	82,246	26,413	37,510	46,615	35.4	50.1	62.2	26.0	27.1	32.8
City Union Bank	235	255	Hold	2,439	28,298	34,883	41,512	20,142	24,344	29,408	13,262	16,641	19,905	13.4	16.8	20.1	21.1	20.8	22.5
Federal Bank	330	375	Hold	8,550	1,06,574	1,27,004	1,48,958	72,062	85,682	1,04,911	41,173	53,143	65,782	16.7	21.5	25.2	18.2	20.7	26.4
RBL Bank	388	386	Hold	6,324	63,595	75,233	90,541	32,992	44,576	59,618	8,224	16,522	28,512	13.4	13.7	18.4	19.3	34.4	86.2
Small Cap (M-cap <US\$1.5bn)																			
DCB Bank	209	230	Buy	708	24,565	30,279	36,542	12,958	15,638	19,405	7,316	9,212	11,334	23.0	28.6	35.2	22.0	22.4	24.5
Equitas Small Finance Bank	68	85	Buy	813	33,912	43,751	52,394	12,650	17,922	22,232	1,031	8,304	10,667	0.9	7.3	9.3	24.3	32.6	221.7
South Indian Bank	49	62	Buy	1,351	34,374	43,493	50,226	23,734	27,184	33,152	14,551	17,550	20,847	5.6	6.7	8.0	20.9	18.2	19.7
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	PIE (X)			PIBV (X)			RoE (%)			RoA (%)					
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E			
Large Cap (M-cap >US\$5bn)																			
Axis Bank	1,268	1,490	Hold	41,463	16.1	12.4	10.0	1.9	1.7	1.4	12.7	14.4	15.4	1.4	1.6	1.6			
Bandhan Bank	172	200	Hold	2,909	22.6	11.4	9.0	1.1	1.0	0.9	4.9	9.2	10.6	0.6	1.1	1.2			
Bank of Baroda	238	325	Buy	12,944	6.2	6.4	4.9	0.8	0.7	0.7	13.8	12.0	14.2	1.1	0.9	1.0			
HDFC Bank	714	1,020	Buy	1,15,573	14.7	13.4	11.0	2.0	1.8	1.6	14.0	13.8	15.1	1.8	1.8	1.9			
ICICI Bank	1,360	1,820	Buy	1,02,525	19.4	16.4	13.8	2.9	2.5	2.2	15.9	16.4	17.0	2.2	2.3	2.4			
IndusInd Bank	877	1,050	Hold	7,176	73.2	15.8	10.3	1.0	1.0	0.9	1.4	6.4	9.2	0.2	0.7	1.0			
Kotak Mahindra Bank	439	475	Buy	45,847	31.2	26.0	22.7	3.2	2.9	2.6	11.1	11.7	12.0	1.9	2.0	2.0			
Punjab National Bank	117	115	Hold	14,062	7.9	6.9	6.3	0.9	0.8	0.8	12.5	13.0	12.7	0.9	0.9	0.9			
State Bank of India	957	1,275	Buy	92,739	10.9	10.1	8.7	1.6	1.4	1.3	16.2	15.2	15.6	1.1	1.1	1.1			
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
AU Small Finance Bank	992	1,130	Hold	7,821	28.0	19.8	15.9	3.7	3.1	2.6	14.2	17.2	18.0	1.5	1.8	1.8			
City Union Bank	235	255	Hold	2,439	17.5	13.9	11.7	2.2	1.9	1.7	13.2	14.7	15.4	1.5	1.6	1.6			
Federal Bank	330	375	Hold	8,550	19.7	15.3	13.1	2.1	1.9	1.7	11.4	12.9	13.4	1.1	1.3	1.4			
RBL Bank	388	386	Hold	6,324	28.9	28.3	21.1	1.4	1.4	1.3	5.1	6.1	6.2	0.5	1.0	1.3			
Small Cap (M-cap <US\$1.5bn)																			
DCB Bank	209	230	Buy	708	9.1	7.3	5.9	1.0	0.9	0.8	12.0	13.2	14.3	0.9	1.0	1.0			
Equitas Small Finance Bank	68	85	Buy	813	74.9	9.3	7.2	1.3	1.1	1.0	1.7	12.7	14.2	0.2	1.2	1.3			
South Indian Bank	49	62	Buy	1,351	8.8	7.3	6.2	1.1	1.0	0.9	13.5	14.4	14.9	1.1	1.2	1.2			
NBFC																			
Akshat Agrawal (akshat.agrawal@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	Net Interest Income (Rsmn)			Op Profit (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	NII	PPOP	PAT
Large Cap (M-cap >US\$5bn)																			
Housing & Urban Development Corp	164	239	Buy	3,450	41,656	54,733	67,769	39,665	52,539	65,170	40,344	41,421	51,030	20.2	20.7	25.5	27.5	28.2	12.5
Muthoot Finance	2,626	3,000	Hold	11,068	1,71,255	1,90,226	2,21,757	1,41,153	1,51,262	1,76,948	1,01,341	1,08,128	1,26,277	252.4	269.3	314.5	13.8	12.0	11.6
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Manappuram Finance	327	375	Hold	3,222	45,945	62,220	75,541	25,745	39,323	48,979	15,247	25,603	32,850	18.0	26.0	31.8	28.2	37.9	46.8
Aavas Financiers	1,210	1,714	Hold	1,007	11,840	14,257	15,302	8,742	10,626	11,302	6,540	8,020	9,334	82.6	101.1	105.1	13.6	13.7	12.8
LIC Housing Finance	564	574	Hold	3,257	89,878	84,277	1,00,561	76,683	78,731	88,702	55,951	58,629	64,422	101.7	107.0	117.0	9.2	7.5	7.3
PNB Housing Finance	1,225	1,216	Hold	3,353	30,270	35,235	41,487	26,176	30,156	36,419	23,279	24,123	26,991	89.3	92.6	103.6	17.1	18.0	7.7
Small Cap (M-cap <US\$1.5bn)																			
Can Fin Homes	736	995	Buy	1,029	16,106	17,712	20,425	13,432	14,614	17,029	1,08,576	1,11,522	1,30,122	81.5	83.7	97.7	12.6	12.6	9.5
Home First Finance	1,094	1,506	Buy	1,201	8,717	9,943	12,534	7,646	8,737	10,313	5,404	6,168	7,234	52.0	59.3	69.6	19.9	16.1	15.7
Repo Home Finance	331	442	Buy	218	7,644	8,520	9,548	5,550	5,999	6,604	4,528	4,282	4,744	72.4	68.5	75.8	11.8	9.1	2.4
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	PIE (X)			PIABV (X)			RoE (%)			RoA (%)					
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E			
Large Cap (M-cap >US\$5bn)																			
Housing & Urban Development Corp	164	239	Buy	3,450	8.1	7.9	6.4	1.5	1.3	1.2	20.2	17.7	19.1	2.7	2.2	2.2			
Muthoot Finance	2,626	3,000	Hold	11,068	10.4	9.8	8.3	2.8	2.2	1.8	30.6	25.5	24.0	0.1	0.1	0.1			
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Manappuram Finance	327	375	Hold	3,222	18.2	12.6	10.3	1.9	1.7	1.4	11.0	14.1	15.0	2.8	3.5	3.8			
Aavas Financiers	1,210	1,714	Hold	1,007	14.6	12.0	11.5	1.9	1.7	1.4	14.0	15.0	13.6	3.3	3.5	3.1			
LIC Housing Finance	564	574	Hold	3,257	5.5	5.3	4.8	0.8	0.7	0.7	14.4	13.4	13.1	1.8	1.7	1.8			
PNB Housing Finance	1,225	1,216	Hold	3,353	13.7	13.2	11.8	1.7	1.5	1.3	12.9	11.8	11.7	2.6	2.4	2.3			
Small Cap (M-cap <US\$1.5bn)																			
Can Fin Homes	736	995	Buy	1,029	9.0	8.8	7.5	1.6	1.4	1.2	19.7	17.2	17.2	2.5	2.4	2.4			
Home First Finance	1,094	1,506	Buy	1,201	21.0	18.4	15.7	2.6	2.3	2.0	15.7	13.3	13.6	3.9	3.7	3.6			
Repo Home Finance	331	442	Buy	218	4.6	4.8	4.4	0.5	0.5	0.4	12.5	10.5	10.6	2.9	2.5	2.5			

NBFC																			
Vinod Rajamani (vinod.rajamani@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$m)	Net Interest Income (Rsmn)			Op Profit (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	NII	PPOP	PAT
Large Cap (M-cap >US\$5bn)																			
Bajaj Finance	983	1,200	Buy	64,234	4,41,101	5,89,381	7,40,462	3,55,473	4,75,430	5,52,239	1,93,324	2,86,236	3,31,676	233.8	294.3	384.7	29.6	24.6	31.0
HDB Financial	609	750	Buy	5,312	89,681	1,03,170	1,19,671	62,017	74,749	89,826	25,443	33,791	41,263	31.0	27.3	30.6	15.5	20.3	27.3
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Poonawalla Fincorp	440	470	Hold	4,071	33,742	52,512	68,401	18,278	30,096	38,667	5,419	10,736	13,448	13.2	13.4	15.4	42.4	45.4	57.5
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$m)	PIE (X)			PIABV (X)			RoE (%)			RoA (%)					
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E			
Large Cap (M-cap >US\$5bn)																			
Bajaj Finance	983	1,200	Buy	64,234	4.2	3.3	2.6	5.2	4.4	3.6	17.9	22.3	21.6	3.8	4.6	4.5			
HDB Financial	609	750	Buy	5,312	19.6	22.3	19.9	2.4	2.1	1.8	13.9	15.1	15.8	2.2	2.5	2.6			
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Poonawalla Fincorp	440	480	Hold	4,071	33.3	32.9	28.7	3.4	2.7	2.6	5.9	9.1	10.0	1.1	1.5	1.4			
Insurance																			
Vinod Rajamani (vinod.rajamani@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$m)	APE (Rsmn)			NBV (Rsmn)			APE/NBV Margin (%)			EVPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	APE	NBV	
Large Cap (M-cap >US\$5bn)																			
HDFC Life Insurance	560	700	Buy	12,773	1,66,410	1,88,093	2,13,568	40,340	46,173	54,993	24.2	24.5	25.7	288.0	331.5	380.8	13.3	16.8	
ICICI Pru Life Insurance	447	660	Buy	6,810	1,06,420	1,19,719	1,34,199	26,290	29,636	33,906	24.7	24.8	25.3	366.6	416.4	469.0	12.3	13.6	
SBI Life Insurance	1,687	2,360	Buy	17,773	2,42,600	2,72,051	3,06,447	66,700	75,497	86,675	27.5	27.8	28.3	806.1	946.5	1,109.7	12.4	14.0	
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Canara HSBC Life Insurance	137	205	Buy	1,362	27,987	32,854	38,247	6,273	7,254	8,534	22.4	22.1	22.3	76.1	89.8	105.8	16.9	16.6	
Max Financial Services	1,325	1,980	Buy	4,802	1,05,030	1,21,182	1,41,754	26,470	30,673	35,832	25.2	25.3	25.3	669.2	794.9	942.7	16.2	16.3	
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$m)	PIEV (X)			PIBV (X)			RoE (%)			RoEV (%)					
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E			
Large Cap (M-cap >US\$5bn)																			
HDFC Life Insurance	560	700	Buy	12,773	1.9	1.7	1.5	6.8	6.0	5.5	11.3	10.9	10.3	12.1	15.9	14.9			
ICICI Pru Life Insurance	447	660	Buy	6,810	1.2	1.1	1.0	4.7	4.2	3.8	12.6	12.7	11.9	10.5	13.6	12.6			
SBI Life Insurance	1,687	2,360	Buy	17,773	2.1	1.8	1.5	8.9	7.7	6.7	13.7	15.0	15.0	15.0	17.4	17.2			
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Canara HSBC Life Insurance	137	205	Buy	1,362	1.8	1.5	1.3	8.1	7.6	7.2	8.1	8.0	8.4	18.4	17.9	17.9			
Max Financial Services	1,325	1,980	Buy	4,802	2.0	1.7	1.4	7.3	6.9	6.4	4.4	5.8	7.1	14.6	18.8	18.6			
Auto NBFC																			
Vinod Rajamani (vinod.rajamani@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$m)	Net Interest Income (Rsmn)			Op Profit (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	NII	PPOP	PAT
Large Cap (M-cap >US\$5bn)																			
Cholamandalam Investment and Finance	1,621	1,800	Hold	14,538	1,39,984	1,73,326	1,99,731	1,04,965	1,30,724	1,52,135	52,196	72,189	87,000	41.6	56.2	79.0	19.4	20.4	29.1
Shriram Finance	988	1,190	Buy	24,407	2,51,236	3,14,310	3,78,715	1,86,313	2,30,274	2,62,233	99,981	1,29,283	1,58,251	192.0	236.4	281.7	22.8	18.6	25.8
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Mahindra & Mahindra Financial	326	390	Hold	4,754	88,196	1,00,189	1,16,214	62,312	73,520	91,025	27,823	36,602	49,637	14.3	18.5	26.2	14.8	20.9	33.6
Sundaram Finance	4,237	4,650	Hold	4,942	29,300	33,269	40,025	29,011	30,726	36,077	18,342	19,331	24,314	118.8	125.0	143.7	16.9	11.5	15.1
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$m)	PIE (X)			PIBV (X)			RoE (%)			RoA (%)					
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E			
Large Cap (M-cap >US\$5bn)																			
Cholamandalam Investment and Finance	1,621	1,800	Hold	14,538	38.9	28.8	20.5	4.5	3.7	3.0	19.3	21.3	21.0	2.3	2.7	2.8			
Shriram Finance	988	1,190	Buy	24,407	5.1	4.2	3.5	14.1	9.1	8.2	16.4	13.2	11.5	3.3	3.4	3.3			
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Mahindra & Mahindra Financial	326	390	Hold	4,754	22.9	17.6	12.4	1.8	1.6	1.4	12.5	13.8	16.2	2.0	2.2	2.4			
Sundaram Finance	4,237	4,650	Hold	4,942	35.7	33.9	29.5	3.7	3.2	2.7	15.4	14.0	15.1	2.9	2.7	2.9			

Consumer Durables & Consumer Electricals																			
Rabindra Nath Nayak (rabindranath.nayak@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$m)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Large Cap (M-cap >US\$5bn)																			
Havells India	1,082	1,305	Buy	7,128	2,25,278	2,58,457	2,89,425	21,997	23,727	27,981	16,310	15,481	18,732	26.0	24.7	29.8	13.3	12.8	7.2
Polycab India	8,290	9,004	Hold	13,116	2,88,838	3,82,626	4,52,511	40,057	51,442	61,758	26,720	35,107	43,269	177.5	233.2	287.4	25.2	24.2	27.3
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Bajaj Electricals	304	386	Hold	368	44,622	49,093	53,649	1,513	2,676	3,327	(637)	1,292	1,739	(5.5)	11.2	15.1	9.6	48.3	#NUM!
Blue Star	1,592	1,834	Buy	3,436	1,24,020	1,31,842	1,60,930	9,304	9,233	11,487	5,665	5,731	7,604	27.6	27.9	37.0	13.9	11.1	15.9
Crompton Greaves Consumer Electricals	212	365	Buy	1,430	80,955	91,857	1,05,419	8,274	10,143	12,578	5,143	6,245	7,472	8.0	9.7	11.6	14.1	23.3	20.5
Dixon Technologies India	12,745	14,671	Hold	8,185	4,88,728	7,48,507	9,84,402	18,665	24,706	38,192	8,446	11,854	19,243	138.2	194.0	314.9	41.9	43.0	50.9
V-Guard Industries	291	404	Buy	1,332	59,658	68,435	78,974	5,268	6,863	8,229	3,526	4,286	5,495	8.1	9.8	12.6	15.1	25.0	24.8
Voltas	1,041	1,096	Hold	3,616	1,42,445	1,64,096	1,93,902	6,469	9,588	13,665	4,024	6,284	10,248	12.2	19.0	31.0	16.7	45.3	59.6
Whirlpool of India	800	802	Hold	1,065	80,342	91,357	99,901	4,811	3,746	5,694	2,938	2,339	3,566	23.2	18.4	28.1	11.5	8.8	10.2
PG Electroplast Ltd	524	600	Hold	1,578	52,880	68,315	1,02,175	3,870	5,207	8,484	1,966	2,519	4,020	6.9	8.8	14.1	39.0	48.1	43.0
Small Cap (M-cap <US\$1.5bn)																			
Amber Enterprises India	6,640	8,376	Buy	2,458	1,21,865	1,47,844	2,79,618	9,523	12,352	16,714	3,068	4,736	6,988	87.0	134.3	198.1	51.5	32.5	50.9
IFB Industries	1,187	1,618	Buy	505	54,433	62,714	71,853	3,014	3,400	4,100	1,333	1,726	2,217	32.3	41.8	53.7	14.9	16.6	28.9
Orient Electric	172	255	Buy	386	33,264	38,253	43,728	2,291	2,831	3,496	1,060	1,491	1,717	5.0	7.0	8.0	6.3	23.5	27.3
Stove Kraft	814	821	Hold	283	16,074	19,069	21,621	1,661	2,098	2,443	420	619	874	12.7	18.7	26.4	18.2	21.3	44.3
EPACK Durables	177	244	Hold	179	18,945	29,024	38,788	1,139	1,942	2,980	33	235	667	0.3	2.5	7.0	4.7	61.7	352.5
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$m)	P/E (X)			EV/EBITDA (X)			P/BV (X)			RoE (%)			RoCE (%)		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Large Cap (M-cap >US\$5bn)																			
Havells India	1,082	1,305	Buy	7,128	41.6	43.9	36.3	30.3	28.1	23.8	7.2	6.9	6.1	18.7	16.1	18.0	16.8	16.8	18.8
Polycab India	8,290	9,004	Hold	13,116	46.7	35.6	28.8	31.0	24.1	20.1	10.4	8.6	7.0	22.3	24.3	24.4	29.4	31.9	31.3
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Bajaj Electricals	304	386	Hold	368	(55.1)	27.2	20.2	21.5	12.2	9.8	2.2	2.1	1.9	(5.7)	7.9	9.3	0.6	8.2	8.8
Blue Star	1,592	1,834	Buy	3,436	57.8	57.1	43.0	35.4	35.7	28.7	9.5	6.1	5.6	16.2	13.2	13.5	20.5	15.7	16.4
Crompton Greaves Consumer Electricals	212	365	Buy	1,430	26.5	21.8	18.2	16.2	13.2	10.7	4.6	4.3	3.7	16.5	20.7	22.4	17.3	23.0	25.3
Dixon Technologies India	12,745	14,671	Hold	8,185	92.2	65.7	40.5	41.5	31.4	20.3	16.6	14.1	10.5	18.1	21.6	26.2	24.7	30.9	38.8
V-Guard Industries	291	404	Buy	1,332	36.0	29.6	23.1	24.0	18.4	15.4	5.3	5.0	4.3	13.8	17.5	20.0	18.0	22.0	24.3
Voltas	1,041	1,096	Hold	3,616	85.6	54.8	33.6	53.5	36.1	25.3	5.4	5.3	4.7	5.8	9.7	14.7	7.6	11.7	16.2
Whirlpool of India	800	802	Hold	1,065	34.5	43.4	28.5	15.8	20.3	13.3	2.4	2.3	2.2	7.2	5.5	8.0	6.7	3.5	6.4
PG Electroplast Ltd	524	600	Hold	1,578	76.1	59.4	37.2	39.1	29.1	17.8	4.9	4.5	4.0	6.7	7.9	11.5	6.9	8.2	12.1
Small Cap (M-cap <US\$1.5bn)																			
Amber Enterprises India	6,640	8,376	Buy	2,458	76.3	49.4	33.5	26.5	20.4	15.1	5.4	5.0	4.3	5.3	7.6	13.8	9.8	8.8	10.9
IFB Industries	1,187	1,618	Buy	505	36.7	28.4	22.1	15.7	13.9	11.5	4.9	4.2	3.5	14.4	16.0	17.4	18.3	19.7	21.8
Orient Electric	172	255	Buy	386	34.7	24.7	21.4	16.0	13.0	10.5	4.8	4.5	4.0	13.2	18.4	19.7	21.4	27.1	27.7
Stove Kraft	814	821	Hold	283	64.2	43.5	30.9	16.1	12.7	10.9	5.3	4.9	4.3	8.6	11.7	14.7	15.1	18.2	18.4
EPACK Durables	177	244	Hold	179	519.6	72.0	25.4	21.0	12.3	8.0	1.8	1.7	1.6	0.3	2.4	6.6	2.6	5.3	7.8
Capital Goods																			
Rabindra Nath Nayak (rabindranath.nayak@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$m)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Small Cap (M-cap <US\$1.5bn)																			
Jyoti CNC Automation	1,022	1,153	Buy	2,441	20,931	29,344	37,920	5,268	7,453	9,648	3,360	4,421	6,127	14.8	19.4	26.9	34.6	35.3	35.0
Sterite Technologies	963	1,340	Buy	5,199	47,450	96,256	1,29,008	5,860	22,128	30,960	560	12,784	16,731	1.1	22.8	33.1	64.9	129.9	446.6
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$m)	P/E (X)			EV/EBITDA (X)			P/BV (X)			RoE (%)			RoCE (%)		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Small Cap (M-cap <US\$1.5bn)																			
Jyoti CNC Automation	1,022	1,153	Buy	2,441	69.2	52.6	37.9	45.5	32.1	24.8	11.6	9.5	7.6	18.2	19.9	22.3	13.6	16.1	18.6
Sterite Technologies	963	1,340	Buy	5,199	845.1	42.3	29.1	87.1	23.1	16.5	20.8	20.8	20.8	2.5	23.1	23.2	3.5	20.9	23.9

Cement																			
Girija Shankar Ray (girijashankar.ray@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Large Cap (M-cap >US\$5bn)																			
Ambuja Cements	350	556	Buy	9,130	4,06,557	4,46,947	4,92,368	65,389	77,246	92,791	45,028	25,636	34,788	18.2	10.4	14.1	10.0	19.1	(12.1)
Dalmia Bharat	1,654	2,083	Buy	3,257	1,48,040	1,55,908	1,62,230	30,830	32,341	39,016	11,585	11,195	13,960	61.8	59.7	74.4	10.9	12.5	9.8
Shree Cement	22,225	28,758	Hold	8,418	1,93,105	2,16,005	2,37,741	41,912	46,636	54,182	17,063	17,045	20,334	472.9	472.4	563.6	11.0	13.7	9.2
UltraTech Cement	10,750	13,662	Buy	33,256	8,85,115	9,74,662	10,61,038	1,70,202	1,92,988	2,22,570	82,696	98,201	1,16,598	281.1	333.9	396.4	9.5	14.4	18.7
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
JK Cement	4,888	6,120	Hold	3,965	1,37,223	1,55,513	1,73,327	23,743	27,818	31,996	10,252	12,899	14,805	132.7	166.9	191.6	12.4	16.1	20.2
The Ramco Cements	809	1,084	Buy	2,007	90,126	96,709	1,14,150	14,382	16,216	19,905	2,787	3,872	6,901	11.8	16.4	29.2	12.5	17.6	57.4
Nuvoco Vistas Corp	317	451	Buy	1,190	1,13,383	1,21,525	1,37,721	18,569	18,178	22,160	3,959	3,360	5,838	11.1	9.4	16.3	10.2	9.2	21.4
Small Cap (M-cap <US\$1.5bn)																			
Birla Corp	806	1,234	Buy	651	96,556	1,07,129	1,10,548	14,544	15,261	17,609	5,625	6,024	7,452	73.0	78.2	96.8	7.0	10.0	15.1
JK Lakshmi Cement	477	693	Buy	622	67,626	72,236	75,035	10,107	10,986	12,930	4,261	4,286	4,458	34.3	34.5	35.9	5.3	13.1	2.3
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	P/E (X)			EV/EBITDA (X)			PBV (X)			RoE (%)			RoCE (%)		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Large Cap (M-cap >US\$5bn)																			
Ambuja Cements	350	556	Buy	9,130	19.2	33.7	24.9	13.3	11.2	9.4	1.2	1.2	1.1	6.6	3.5	4.5	8.0	2.9	3.9
Dalmia Bharat	1,654	2,083	Buy	3,257	26.8	27.7	22.2	10.7	10.2	8.5	1.7	1.6	1.5	6.5	6.0	7.1	5.9	5.3	5.9
Shree Cement	22,225	28,758	Hold	8,418	47.0	47.0	39.4	17.7	15.9	13.7	3.6	3.4	3.2	7.8	7.4	8.3	9.6	9.3	10.1
UltraTech Cement	10,750	13,662	Buy	33,256	38.2	32.2	27.1	19.5	17.2	14.9	3.9	3.8	3.6	10.7	12.0	13.6	13.1	14.4	16.5
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
JK Cement	4,888	6,120	Hold	3,965	36.8	29.3	25.5	18.3	15.6	13.6	5.3	4.6	4.0	15.6	16.8	16.7	9.7	10.8	10.7
The Ramco Cements	809	1,084	Buy	2,007	68.6	49.4	27.7	15.8	14.0	11.4	2.3	2.2	2.1	3.6	4.6	7.8	6.1	7.1	9.8
Nuvoco Vistas Corp	317	451	Buy	1,190	28.6	33.7	19.4	8.7	8.9	7.3	1.1	1.1	1.0	3.7	2.5	4.6	4.8	4.5	6.0
Small Cap (M-cap <US\$1.5bn)																			
Birla Corp	806	1,234	Buy	651	11.0	10.3	8.3	5.7	5.4	4.7	0.8	0.8	0.7	7.8	7.9	9.1	6.4	6.6	7.5
JK Lakshmi Cement	477	693	Buy	622	13.9	13.8	13.3	7.2	6.6	5.6	1.5	1.4	1.3	11.1	10.6	10.2	8.6	8.2	7.8

Construction																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$m)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY25-FY27E		
					FY25	FY26	FY27E	FY25	FY26	FY27E	FY25	FY26	FY27E	FY25	FY26	FY27E	Sales	EBITDA	PAT
Small Cap (M-cap <US\$1.5bn)																			
Ashoka Buldcon	107	109	Hold	314	70,614	60,679	66,308	5,469	5,781	6,204	1,970	2,045	2,954	7.0	13.2	10.5	(3.1)	6.5	22.4
KNR Constructions	114	101	Sell	335	33,586	20,806	22,794	6,259	2,020	2,345	7,407	1,270	1,420	25.8	4.5	5.0	(17.6)	(38.8)	(56.2)
PNC InfraTech	155	214	Hold	419	55,131	46,335	55,664	10,489	5,829	6,845	7,056	3,396	3,694	27.5	13.4	14.4	0.5	(19.2)	(27.6)
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$m)	PIE (X)			EV/EBITDA (X)			PBV (X)			RoE (%)			RoCE (%)		
					FY25	FY26	FY27E	FY25	FY26	FY27E	FY25	FY26	FY27E	FY25	FY26	FY27E	FY25	FY26	FY27E
Small Cap (M-cap <US\$1.5bn)																			
Ashoka Buldcon	107	109	Hold	314	15.2	8.1	10.1	8.8	8.3	7.8	0.7	0.6	0.6	5.1	7.7	5.7	5.8	5.7	5.7
KNR Constructions	114	101	Sell	335	4.4	25.2	22.5	4.9	15.1	13.0	0.8	0.6	0.6	19.2	2.8	2.8	20.8	3.1	2.9
PNC InfraTech	155	214	Hold	419	5.7	11.6	10.8	3.5	6.4	5.4	0.7	0.7	0.6	13.6	6.0	6.0	12.2	6.0	6.7
Defence																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$m)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY25-FY27E		
					FY25	FY26	FY27E	FY25	FY26	FY27E	FY25	FY26	FY27E	FY25	FY26	FY27E	Sales	EBITDA	PAT
Large Cap (M-cap >US\$5bn)																			
Bharat Electronics	380	497	Buy	29,161	2,37,688	2,76,101	3,27,648	68,337	80,493	92,731	53,214	60,620	71,131	7.3	8.3	9.7	17.4	16.5	15.6
Hindustan Aeronautics	4,869	5,432	Buy	34,185	3,09,810	3,30,888	3,96,671	96,081	97,698	1,17,843	83,582	91,185	1,03,222	125.0	136.3	154.3	13.2	10.7	11.1
Mazagon Dock Shipbuilders	2,120	3,158	Buy	8,978	1,14,319	1,30,063	1,40,468	20,600	24,262	27,182	24,135	27,556	30,272	59.8	68.3	75.0	10.8	14.9	12.0
Solar Industries India	20,087	19,995	Buy	19,082	75,502	98,377	1,38,305	19,604	26,218	37,995	10,098	16,776	26,813	111.6	185.4	296.3	35.3	39.2	62.9
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Bharat Dynamics	1,126	1,434	Buy	4,333	33,451	39,422	50,619	4,724	4,801	7,184	5,496	6,019	7,895	15.0	16.4	21.5	23.0	23.3	19.8
Bharat Earth Movers	1,977	2,000	Buy	1,729	40,222	44,237	51,990	5,057	4,466	6,490	2,925	2,541	3,980	35.1	30.5	47.8	13.7	13.3	16.6
Data Patterns	4,143	4,156	Hold	2,435	7,084	9,248	12,100	2,850	3,740	4,737	2,218	2,744	3,386	39.6	49.0	60.5	30.7	28.9	23.6
Small Cap (M-cap <US\$1.5bn)																			
Astra Microwave Products	1,674	1,139	Buy	1,668	10,512	11,558	13,700	2,690	3,081	3,625	1,535	1,710	1,957	16.2	18.0	20.6	14.2	16.1	12.9
Paras Defence and Space Technologies	1,292	863	Hold	1,093	3,647	4,766	6,203	972	1,205	1,658	635	854	1,111	7.9	10.6	13.8	30.4	30.6	32.3
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$m)	PIE (X)			EV/EBITDA (X)			PBV (X)			RoE (%)			RoCE (%)		
					FY25	FY26	FY27E	FY25	FY26	FY27E	FY25	FY26	FY27E	FY25	FY26	FY27E	FY25	FY26	FY27E
Large Cap (M-cap >US\$5bn)																			
Bharat Electronics	380	497	Buy	29,161	52.2	45.8	39.1	39.3	33.3	28.9	13.9	11.6	9.8	29.3	27.6	27.2	33.0	32.3	31.7
Hindustan Aeronautics	4,869	5,432	Buy	34,185	39.0	35.7	31.5	29.9	29.4	24.4	9.3	7.9	6.8	26.1	24.0	23.2	15.9	11.2	10.7
Mazagon Dock Shipbuilders	2,120	3,158	Buy	8,978	35.4	31.0	28.2	33.7	28.6	25.5	10.8	8.6	6.7	34.0	30.7	26.6	27.4	25.4	21.9
Solar Industries India	20,087	19,995	Buy	19,082	180.0	108.4	67.8	92.8	69.4	47.9	41.4	29.0	20.9	26.3	31.5	35.8	36.3	35.3	37.8
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Bharat Dynamics	1,126	1,434	Buy	4,333	75.1	68.6	52.3	78.5	77.2	51.6	10.3	9.7	8.6	14.4	14.6	17.4	5.5	5.4	8.1
Bharat Earth Movers	1,977	2,000	Buy	1,729	56.3	64.8	41.4	33.0	37.4	25.7	5.7	5.3	4.8	10.5	8.5	12.1	14.8	11.2	16.1
Data Patterns	4,143	4,156	Hold	2,435	104.6	84.6	68.5	81.0	61.7	48.7	15.4	13.4	11.6	15.7	16.9	18.1	19.1	21.6	23.8
Small Cap (M-cap <US\$1.5bn)																			
Astra Microwave Products	1,674	1,139	Buy	1,668	103.6	93.0	81.2	60.3	52.6	44.7	14.5	12.8	11.2	14.9	14.6	14.7	20.8	20.6	21.7
Paras Defence and Space Technologies	1,292	863	Hold	1,093	164.0	121.9	93.7	106.2	85.7	62.2	16.3	14.4	12.4	11.8	12.5	14.2	14.6	14.7	18.1

Consumer Staples																			
Operational Metrics																			
Company	CMP	TP (Rs)	Current Rating	M-cap (US\$mn)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
	(Rs)				FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Large Cap (M-cap >US\$5bn)																			
Britannia Industries	4,801	6,630	Buy	12,141	1,91,516	2,08,956	2,35,068	35,444	37,983	44,588	25,335	26,646	31,618	105.2	110.6	131.3	10.8	12.2	11.7
Colgate-Palmolive India	1,801	2,200	Hold	5,142	60,350	64,836	69,215	18,697	20,419	21,991	13,503	15,069	16,155	49.6	55.4	59.4	7.1	8.5	9.4
Dabur India	379	475	Hold	7,054	1,31,926	1,38,649	1,47,841	24,518	25,099	27,806	18,855	18,872	21,108	10.6	10.6	11.9	5.9	6.5	5.8
Godrej Consumer Products	854	1,175	Hold	9,176	1,51,779	1,65,425	1,79,677	31,562	33,418	38,882	20,946	22,125	26,402	20.5	21.6	25.8	8.8	11.0	12.3
Hindustan Unilever	1,876	2,250	Hold	46,262	6,44,680	6,85,013	7,33,015	1,50,540	1,56,756	1,72,007	1,09,020	1,09,609	1,19,937	46.4	46.6	51.0	6.6	6.9	4.9
ITC	261	320	Hold	34,334	7,19,838	7,50,469	7,93,199	3,60,131	2,85,751	2,91,208	3,13,013	2,01,881	2,05,627	25.0	16.1	16.4	5.0	(10.1)	(18.9)
Marico	783	895	Hold	10,685	1,36,110	1,50,323	1,64,144	23,280	27,650	32,998	17,620	20,297	24,316	13.6	15.6	18.7	9.8	19.1	17.5
Nestle India	1,334	1,540	Hold	27,005	2,31,546	2,61,649	3,01,711	53,061	60,354	74,055	34,238	38,600	48,000	17.8	20.0	24.9	14.2	18.1	18.4
P&G Hygiene & Health Care	6,982	11,630	Buy	2,379	42,904	47,195	52,386	11,241	11,563	12,625	8,565	8,651	9,449	263.5	266.2	290.8	10.5	6.0	5.0
Tata Consumer Products	960	1,310	Buy	9,974	2,02,904	2,32,144	2,64,255	27,918	33,752	40,916	15,624	19,768	25,580	15.8	20.0	25.8	14.1	21.1	28.0
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Emami	374	445	Hold	1,712	37,795	40,268	42,937	9,637	11,602	11,862	8,536	9,661	9,460	19.6	22.1	21.5	6.6	10.9	5.3
Gillette India	7,020	9,170	Buy	2,401	30,995	34,620	36,900	9,431	10,190	10,946	6,542	7,094	7,597	200.7	193.8	215.2	9.1	7.7	7.8
Valuation Metrics																			
Company	CMP	TP (Rs)	Current Rating	M-cap (US\$mn)	PIE (X)			EV/EBITDA (X)			PIBV (X)			RoE (%)			RoCE (%)		
	(Rs)				FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Large Cap (M-cap >US\$5bn)																			
Britannia Industries	4,801	6,630	Buy	12,141	45.7	43.4	36.6	32.5	30.3	25.8	22.6	20.6	18.6	54.3	49.7	53.4	40.9	38.0	41.5
Colgate-Palmolive India	1,801	2,200	Hold	5,142	36.3	32.5	30.3	25.4	23.3	21.6	30.9	30.9	30.9	83.1	95.1	102.0	84.4	97.4	104.4
Dabur India	379	475	Hold	7,054	35.6	35.6	31.8	25.8	25.2	22.8	6.0	5.7	5.5	17.0	16.3	17.6	15.9	15.2	16.5
Godrej Consumer Products	854	1,175	Hold	9,176	41.7	39.5	33.1	28.1	26.5	22.8	6.9	6.9	6.9	28.1	17.1	19.1	13.1	14.5	16.3
Hindustan Unilever	1,876	2,250	Hold	46,262	40.4	40.2	36.7	28.8	27.6	25.2	9.0	9.0	9.0	22.1	22.4	24.6	21.6	21.8	24.0
ITC	261	320	Hold	34,334	10.4	16.2	15.9	8.5	10.7	10.5	4.1	4.0	4.0	42.3	25.0	25.2	38.7	25.1	25.3
Marico	783	895	Hold	10,685	57.8	50.1	41.9	42.8	36.1	30.2	24.2	21.4	19.0	43.1	45.3	48.1	26.8	27.2	30.3
Nestle India	1,334	1,540	Hold	27,005	53.6	66.6	75.1	48.2	42.4	34.6	48.4	40.9	33.8	72.6	66.5	69.1	68.4	68.5	70.8
P&G Hygiene & Health Care	6,982	11,889	Buy	2,379	26.5	26.2	24.0	19.2	18.7	17.1	30.1	27.0	24.3	114.9	108.6	106.5	124.4	122.1	119.7
Tata Consumer Products	960	1,310	Buy	9,974	60.8	48.1	37.1	33.3	27.5	22.7	4.4	4.2	4.0	7.5	8.9	11.0	6.2	7.3	8.8
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Emami	374	445	Hold	1,712	19.1	16.9	17.4	16.1	13.4	13.1	5.6	4.4	4.0	30.4	29.0	24.3	37.4	34.4	28.4
Gillette India	7,020	9,170	Buy	2,401	35.0	36.2	32.6	24.0	22.2	20.7	24.2	21.1	15.6	66.4	69.8	59.6	67.3	70.9	60.6
Consumer Discretionary																			
Operational Metrics																			
Company	CMP	TP (Rs)	Current Rating	M-cap (US\$mn)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
	(Rs)				FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Large Cap (M-cap >US\$5bn)																			
Asian Paints	2,376	2,825	Hold	23,926	3,55,835	3,86,100	4,14,650	66,959	75,358	84,632	44,830	50,449	57,299	46.7	52.6	62.7	7.9	12.4	13.1
Berger Paints India	477	570	Hold	5,839	1,18,803	1,27,831	1,37,802	18,333	20,149	22,134	11,802	12,975	14,355	10.1	11.1	12.3	7.7	9.9	10.3
Jubilant Foodworks	425	510	Hold	2,944	95,125	1,05,960	1,18,192	18,878	20,871	23,578	3,387	5,083	6,044	5.1	7.7	9.2	11.5	11.8	33.6
United Breweries	1,200	1,595	Hold	3,330	92,399	1,00,900	1,11,999	8,055	8,032	12,317	3,722	3,687	6,886	14.1	13.9	26.0	10.1	23.7	36.0
United Spirits	1,371	1,676	Buy	10,470	1,24,480	1,36,578	1,52,547	22,960	25,198	29,396	19,210	18,953	22,333	26.5	26.1	30.8	10.7	13.2	7.8
Small Cap (M-cap <US\$1.5bn)																			
Restaurant Brands Asia	90	77	Hold	672	28,226	31,163	35,451	3,283	4,019	5,142	(2,019)	(1,475)	(692)	(3.5)	(2.5)	(1.2)	12.1	25.2	(41.5)
Westlife Foodworld	595	585	Buy	974	26,256	29,144	32,495	3,368	3,701	5,034	(28)	(163)	713	(0)	(1.0)	4.6	11.2	22.2	#NUM!
Valuation Metrics																			
Company	CMP	TP (Rs)	Current Rating	M-cap (US\$mn)	PIE (X)			EV/EBITDA (X)			PIBV (X)			RoE (%)			RoCE (%)		
	(Rs)				FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Large Cap (M-cap >US\$5bn)																			
Asian Paints	2,376	2,825	Hold	23,926	50.8	45.2	37.9	33.2	29.5	26.3	10.7	9.9	9.5	22.0	22.8	24.4	17.8	21.4	22.7
Berger Paints India	477	570	Hold	5,839	47.1	42.9	38.7	29.9	27.2	24.8	6.7	6.0	5.4	18.1	17.8	17.7	15.7	15.4	16.8
Jubilant Foodworks	425	510	Hold	2,944	82.8	55.2	46.4	15.6	14.1	12.5	12.2	10.5	14.3	14.8	19.0	30.7	10.5	19.6	22.2
United Breweries	1,200	1,595	Hold	3,330	85.2	86.0	46.1	40.3	40.4	26.3	7.0	6.8	6.4	8.4	8.0	14.3	8.1	7.2	12.2
United Spirits	1,371	1,676	Buy	10,470	51.7	52.4	44.5	42.6	38.8	33.3	11.4	10.1	9.1	22.0	19.2	20.3	24.0	20.8	21.8
Small Cap (M-cap <US\$1.5bn)																			
Restaurant Brands Asia	90	77	Hold	672	(26.0)	(35.5)	(75.7)	20.2	16.5	12.9	7.3	9.1	10.4	(24.8)	(22.8)	(12.8)	(1.1)	5.7	15.1
Westlife Foodworld	595	585	Buy	974	(3,304.4)	(567.6)	130.1	28.0	25.5	18.8	15.0	15.4	13.8	(0.5)	(2.7)	11.2	9.9	10.0	19.1
Please note: FY25 for PGHH and Gillette is a 9 month period as the company is transitioning from a June year-end company to March year-end																			

Information Technology																			
Shubham Dalia (shubham.dalia@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Large Cap (M-cap >US\$5bn)																			
HCL Technologies	1,326	949	Sell	37,776	13,01,440	14,05,823	14,55,565	2,23,970	2,46,543	2,48,020	1,73,710	1,89,838	1,87,253	61.5	70.0	69.1	5.8	5.2	3.8
Infobays	1,062	984	Sell	45,250	17,86,500	19,55,043	19,99,605	3,62,540	3,86,798	3,97,235	2,94,740	2,93,959	3,01,688	72.8	72.5	74.4	5.8	4.7	1.2
LTIMindtree	4,215	3,235	Sell	13,125	4,23,076	4,65,550	4,98,514	65,011	72,476	79,578	49,827	59,346	64,511	168.4	200.0	217.4	8.5	10.6	13.8
Tata Consultancy Services	2,269	1,724	Sell	86,196	26,70,210	28,05,209	27,45,916	6,68,380	6,79,155	6,65,895	4,92,170	5,20,943	5,09,158	136.0	145.4	140.7	1.4	(0.2)	1.7
Tech Mahindra	1,544	1,187	Sell	15,882	5,68,154	6,42,524	6,79,431	71,525	92,549	1,02,747	48,109	67,654	78,446	54.3	76.3	88.5	9.4	19.9	27.7
Wipro	169	151	Sell	17,574	9,26,240	9,68,116	9,82,265	1,49,398	1,51,738	1,54,689	1,32,655	1,30,559	1,31,133	12.6	13.2	13.3	3.0	1.8	(0.6)
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Birlasoft	297	327	Hold	871	53,099	56,854	61,243	7,450	8,095	8,613	5,183	6,239	6,533	18.6	22.3	23.4	7.4	7.5	12.3
Coloforge	1,929	1,971	Hold	8,972	1,63,128	2,49,110	2,90,395	23,373	38,170	45,486	16,743	24,961	31,076	46.1	58.0	72.5	33.4	39.5	36.2
Mphasis	2,466	2,375	Hold	4,944	1,58,797	1,81,370	2,01,049	24,282	27,110	30,157	18,628	21,167	23,722	97.8	110.9	124.3	12.5	11.4	12.8
Persistent Systems	5,988	5,734	Hold	9,942	1,47,485	1,83,062	2,14,130	23,035	29,490	35,211	18,651	23,732	28,539	119.1	151.8	182.6	20.5	23.6	23.7
Zensar Technologies	479	553	Hold	1,145	56,874	61,928	66,331	8,249	8,371	9,173	7,746	7,855	8,942	34.4	34.9	39.5	8.0	5.4	7.4
KPIT Technologies	514	672	Hold	1,479	64,549	68,324	76,795	9,573	8,632	10,716	6,374	5,498	7,658	23.4	20.2	28.0	9.1	5.8	9.6
Tata Elxsi	3,427	3,857	Hold	2,241	37,575	42,437	46,947	7,531	9,166	10,816	7,242	8,000	9,597	116.2	128.4	154.1	11.8	19.8	15.1
Tata Technologies	744	725	Hold	3,170	55,055	67,811	76,570	7,079	9,572	11,560	4,343	7,755	8,925	13.5	19.1	22.0	17.9	27.8	43.4
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	P/E (X)			EV/EBITDA (X)			P/BV (X)			RoE (%)			RoCE (%)		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Large Cap (M-cap >US\$5bn)																			
HCL Technologies	1,326	949	Sell	37,776	21.6	18.9	19.2	14.7	13.4	13.3	4.8	4.8	4.7	24.0	25.4	25.0	22.9	24.6	24.6
Infobays	1,062	984	Sell	45,250	14.6	14.6	14.3	11.2	10.5	10.2	1.1	1.2	1.1	31.1	32.1	32.2	25.8	27.2	27.6
LTIMindtree	4,215	3,235	Sell	13,125	25.0	21.1	19.4	17.2	15.5	14.1	5.2	4.7	4.0	21.3	23.2	22.2	19.4	19.7	19.2
Tata Consultancy Services	2,269	1,724	Sell	86,196	16.7	15.6	16.1	11.6	11.4	11.6	7.5	6.9	6.2	47.7	45.8	40.5	48.9	44.7	39.7
Tech Mahindra	1,544	1,187	Sell	15,882	28.4	20.2	17.4	20.0	15.4	13.9	2.8	2.6	2.4	16.6	21.7	23.0	17.9	21.6	22.0
Wipro	169	151	Sell	17,574	13.4	12.8	12.7	8.7	8.6	8.4	2.0	2.0	1.8	15.4	15.0	14.8	11.2	11.3	11.0
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Birlasoft	297	327	Hold	871	16.0	13.3	12.7	10.6	9.7	9.1	2.0	1.8	1.6	13.7	14.4	13.6	12.7	13.3	12.8
Coloforge	1,929	1,971	Hold	8,972	41.9	33.3	26.6	36.3	22.2	18.7	6.8	3.5	3.2	16.5	14.8	12.5	20.8	17.0	13.7
Mphasis	2,466	2,375	Hold	4,944	25.2	22.2	19.8	19.0	17.0	15.3	2.6	2.5	2.3	18.3	18.8	19.2	15.6	15.5	16.0
Persistent Systems	5,988	5,734	Hold	9,942	50.3	39.4	32.8	40.2	31.4	26.3	12.0	9.7	7.9	26.3	27.1	26.4	25.0	23.1	20.6
Zensar Technologies	479	553	Hold	1,145	13.9	13.7	12.1	10.6	10.4	9.5	2.3	2.1	1.9	17.6	15.8	16.3	13.0	11.6	11.7
KPIT Technologies	514	672	Hold	1,479	21.9	25.5	18.4	13.7	15.2	12.3	3.9	3.6	3.2	19.7	14.8	18.4	20.0	15.0	16.7
Tata Elxsi	3,427	3,857	Hold	2,241	29.5	26.7	22.2	33.6	27.6	23.4	7.0	6.4	5.7	23.8	23.9	25.4	18.9	20.4	21.7
Tata Technologies	744	725	Hold	3,170	55.3	38.9	33.8	41.5	30.7	25.4	7.7	8.1	7.3	11.6	20.2	22.7	11.3	15.1	18.3
Power																			
Shibangi Choudhury (shibangi.choudhury@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Small Cap (M-cap <US\$1.5bn)																			
Insulation Energy	76	141	Buy	176	21,460	33,076	52,927	2,871	4,817	11,289	2,006	2,855	5,915	9.0	13.0	25.0	57.0	98.3	71.7
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	P/E (X)			EV/EBITDA (X)			P/BV (X)			RoE (%)			RoCE (%)		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Small Cap (M-cap <US\$1.5bn)																			
Insulation Energy	76	141	Buy	176	8.4	5.8	3.0	8.8	5.3	2.2	2.0	1.5	1.0	25.0	27.0	34.0	12.0	8.0	13.0

Others																			
Abhishek Navalgund (abhishek.navalgund@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Small Cap (M-cap <US\$1.5bn)																			
CCL Products India	1,073	1,400	Buy	1,504	44,574	47,699	54,721	7,329	8,476	9,615	3,881	5,065	6,072	29.2	38.1	45.6	10.8	14.5	25.1
LA Opale RG	156	230	Buy	182	3,091	3,555	4,148	1,157	1,283	1,497	941	1,121	1,325	8.5	10.1	11.9	15.8	13.7	18.7
Mold-Tek Packaging	333	900	Buy	233	8,866	10,142	11,637	1,724	2,037	2,388	723	881	1,124	21.9	26.7	34.0	14.6	17.7	24.7
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	PIE (X)			EV/EBITDA (X)			PBV (X)			RoE (%)			RoCE (%)		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Small Cap (M-cap <US\$1.5bn)																			
CCL Products India	1,073	1,400	Buy	1,504	36.8	28.2	23.5	21.0	18.2	16.0	6.1	5.3	4.6	18.0	20.1	20.9	13.2	15.3	16.4
LA Opale RG	156	230	Buy	182	18.4	15.4	13.1	10.5	9.5	8.1	2.1	1.9	1.7	11.4	13.0	14.0	8.8	8.9	9.7
Mold-Tek Packaging*	333	450	Buy	233	15.2	12.5	9.8	14.1	11.9	10.2	1.6	1.4	1.3	10.9	12.1	14.0	9.8	10.9	12.3
Hotels																			
Abhishek Navalgund (abhishek.navalgund@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Large Cap (M-cap >US\$5bn)																			
Indian Hotels Co	724	850	Buy	10,821	96,892	1,11,628	1,23,242	31,947	38,036	42,826	18,765	24,191	28,957	14.7	17.0	20.4	12.8	15.8	24.2
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
EIH Ltd	292	348	Buy	1,917	29,396	33,290	37,538	10,238	11,082	12,447	7,604	7,995	8,991	12.2	12.8	14.4	13.0	10.3	8.7
Chalet Hotels	817	950	Buy	1,878	27,698	27,401	28,934	11,874	12,699	13,723	6,460	6,552	7,125	29.4	29.8	32.5	2.2	7.5	5.0
Leela Palaces Hotels & Resorts Ltd	601	592	Buy	2,108	15,273	18,099	21,022	7,429	8,974	10,356	4,121	4,828	5,754	12.3	14.5	17.2	17.3	18.1	18.2
Small Cap (M-cap <US\$1.5bn)																			
Lemon Tree Hotels	112	126	Hold	930	14,445	16,608	18,412	6,912	8,099	9,250	2,538	3,277	4,213	3.2	4.1	5.3	12.9	15.7	28.8
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	PIE (X)			EV/EBITDA (X)			PBV (X)			RoE (%)			RoCE (%)		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Large Cap (M-cap >US\$5bn)																			
Indian Hotels Co	724	850	Buy	10,821	49.3	42.5	35.5	30.9	26.0	23.1	7.9	6.6	5.5	15.5	16.9	16.8	16.0	17.2	16.6
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
EIH Ltd	292	348	Buy	1,917	24.0	22.8	20.3	16.7	15.5	13.8	3.5	3.0	2.7	15.4	14.2	14.0	12.4	12.5	12.6
Chalet Hotels	817	950	Buy	1,878	27.8	27.4	25.2	16.8	15.7	14.5	4.9	4.1	3.5	19.2	16.3	15.1	13.0	11.9	11.6
Leela Palaces Hotels & Resorts Ltd	601	592	Buy	2,108	48.7	41.6	34.9	28.7	23.8	20.6	3.1	2.9	2.7	8.0	7.0	8.0	6.7	6.8	7.4
Small Cap (M-cap <US\$1.5bn)																			
Lemon Tree Hotels	112	126	Hold	930	34.9	27.0	21.0	14.8	12.6	11.0	4.3	3.6	3.0	19.9	21.1	21.8	15.4	16.9	18.1
Specialty Chemicals																			
Abhishek Navalgund (abhishek.navalgund@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Large Cap (M-cap >US\$5bn)																			
SRF	2,492	3,000	Buy	7,755	1,57,865	1,82,448	2,09,248	34,096	45,346	49,801	19,029	24,705	26,906	64.2	83.3	90.7	15.1	20.9	18.9
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Aarti Industries	488	570	Hold	1,858	82,860	1,06,179	1,26,728	11,670	15,918	18,997	4,110	6,344	8,136	11.3	17.5	22.4	23.7	27.6	40.7
Fine Organic Industries	5,423	6,300	Buy	1,745	23,658	28,095	32,782	4,830	6,080	6,469	4,117	4,861	5,157	134.3	158.5	168.2	17.7	15.7	11.9
Navin Fluorine International	8,468	10,000	Buy	4,561	33,139	42,044	50,299	10,817	14,051	17,229	6,687	9,583	11,946	130.7	187.3	233.5	23.2	26.2	33.7
Vinati Organics	1,136	1,550	Buy	1,236	22,269	27,918	33,095	6,539	7,315	8,836	4,437	4,589	5,718	42.8	44.2	55.1	21.9	16.2	13.5
Small Cap (M-cap <US\$1.5bn)																			
Advanced Enzyme Technologies	265	360	Buy	312	7,458	8,700	10,148	2,291	2,405	2,802	1,602	1,651	1,952	14.3	14.8	17.5	16.7	10.6	10.4
Camlin Fine Sciences	91	106	Hold	183	17,233	19,412	23,070	1,069	1,594	2,317	126	517	902	0.7	2.7	4.7	15.7	47.2	167.1
Clean Science & Technology	797	980	Buy	889	9,565	12,532	16,817	3,550	4,324	5,768	2,297	2,911	3,961	21.6	27.4	37.3	32.6	27.5	31.3
Galaxy Surfactants	2,582	3,200	Hold	961	52,483	65,132	72,682	4,753	6,842	7,213	2,770	4,151	4,337	78.1	117.1	122.3	17.7	23.2	25.1
Rossari Biotech	426	660	Buy	248	23,964	27,503	31,125	2,859	3,493	3,953	1,492	1,726	1,934	26.9	31.2	34.9	14.0	17.6	13.9
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	PIE (X)			EV/EBITDA (X)			PBV (X)			RoE (%)			RoCE (%)		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Large Cap (M-cap >US\$5bn)																			
SRF	2,492	3,000	Buy	7,755	38.8	29.9	27.5	22.8	17.1	15.6	5.3	4.6	4.1	14.3	16.4	15.8	14.1	17.4	17.4
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Aarti Industries	488	570	Hold	1,858	43.0	27.9	21.7	18.9	13.8	11.6	3.0	2.8	2.6	7.1	10.3	12.4	6.8	10.1	11.9
Fine Organic Industries	5,423	6,300	Buy	1,745	40.4	34.2	32.2	31.5	25.0	23.5	6.2	5.3	4.5	16.6	16.7	15.1	13.1	13.9	12.5
Navin Fluorine International	8,468	10,000	Buy	4,561	64.8	45.2	36.3	40.1	30.9	25.2	10.9	9.4	8.0	20.3	22.3	23.8	20.1	22.4	24.7
Vinati Organics	1,136	1,550	Buy	1,236	26.5	25.7	20.6	17.7	15.8	13.1	3.7	3.4	3.0	18.3	14.2	16.0	18.0	18.1	19.7
Small Cap (M-cap <US\$1.5bn)																			
Advanced Enzyme Technologies	265	360	Buy	312	18.5	18.0	15.2	10.0	9.5	8.2	1.8	1.7	1.5	10.5	9.8	10.9	12.2	11.4	12.4
Camlin Fine Sciences	91	106	Hold	183	138.0	33.7	19.3	21.1	14.2	9.7	1.7	1.6	1.5	1.3	4.8	7.9	2.2	4.4	7.9
Clean Science & Technology	797	980	Buy	889	36.9	29.1	21.4	22.8	18.7	14.0	5.3	4.7	4.0	15.3	17.1	20.1	18.5	20.7	24.7
Galaxy Surfactants	2,582	3,200	Hold	961	33.0	22.0	21.1	18.0	12.5	11.9	3.3	3.0	2.7	10.8	14.3	13.3	13.0	17.5	16.3
Rossari Biotech	426	660	Buy	248	15.8	13.7	12.2	9.2	7.6	6.7	1.8	1.6	1.4	11.8	12.2	12.1	13.3	13.5	14.5

Pharmaceuticals																			
Niharika Agarwal (niharika.agarwal@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Large Cap (M-cap >US\$5bn)																			
Alkem Laboratories	5,250	5,952	Hold	6,590	1,47,123	1,63,647	1,78,911	30,052	34,662	38,832	24,469	23,453	26,553	204.6	196.1	222.0	10.3	13.7	4.2
Cipla India	1,330	1,615	Buy	11,277	2,81,626	3,16,033	3,42,058	59,249	59,479	73,826	40,836	39,783	50,288	50.6	49.2	62.3	10.2	11.6	11.0
Dr Reddy's Laboratories	1,240	1,098	Sell	10,866	3,35,933	3,10,679	3,50,394	63,531	55,695	71,132	42,849	33,317	43,619	51.4	39.9	52.3	2.1	5.8	0.9
Gland Pharma	3,088	2,885	Hold	5,349	64,307	70,913	80,774	16,295	18,867	22,314	10,273	13,897	17,923	63.4	84.4	108.8	12.1	17.0	32.1
Lupin	1,954	2,669	Hold	9,379	2,79,580	2,96,264	3,18,897	81,595	69,017	75,523	52,544	37,757	44,602	115.0	82.6	97.6	6.8	(3.8)	(7.9)
Mankind Pharma	2,372	2,864	Hold	10,286	1,42,776	1,59,681	1,77,480	36,174	40,833	46,170	19,128	25,568	31,230	46.3	61.9	75.7	11.5	13.0	27.8
Sun Pharmaceutical Industries	1,771	2,437	Buy	44,602	5,84,620	6,44,772	7,02,801	1,64,912	1,87,891	2,12,949	1,24,600	1,36,606	1,72,094	51.9	56.9	71.7	9.6	13.6	17.5
Torrent Pharmaceuticals	4,643	4,904	Hold	18,540	1,39,797	1,90,215	2,15,714	45,585	62,363	71,938	22,294	20,602	24,855	65.9	60.9	73.4	24.2	25.6	5.6
Zydus Lifesciences	1,133	1,274	Hold	11,860	2,71,484	2,99,858	3,34,752	71,946	71,822	85,499	44,468	32,538	58,039	44.2	32.3	57.7	11.0	9.0	14.2
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Ajanta Pharma	3,328	3,282	Hold	4,366	54,529	62,276	69,486	13,948	15,863	18,643	10,560	11,024	13,012	84.0	87.7	103.5	12.9	15.6	11.0
Alembic Pharmaceuticals	798	959	Buy	1,646	73,449	82,287	87,940	11,185	13,668	14,764	7,395	8,024	8,732	37.6	40.8	44.4	9.4	14.9	8.7
Natco Pharma	789	809	Sell	1,489	40,783	33,750	38,204	14,365	8,984	10,354	14,185	8,158	8,601	79.2	45.6	48.0	(3.2)	(15.1)	(22.1)
Pfizer India	4,054	5,212	Hold	1,947	25,197	26,967	28,722	9,041	9,667	10,293	7,588	7,871	8,402	165.9	172.0	189.3	6.8	6.7	5.2
Small Cap (M-cap <US\$1.5bn)																			
Eris Lifesciences	1,150	1,722	Buy	1,675	31,294	36,303	40,414	11,201	13,455	15,313	6,369	6,636	7,757	46.0	47.9	56.0	13.6	16.9	10.4
Indoco Remedies	227	243	Hold	220	18,453	21,445	23,911	1,418	2,251	3,158	(952)	1,218	1,057	(10.3)	13.2	11.5	13.8	49.2	NA
Jubilant Pharmova	943	1,261	Buy	1,576	82,796	94,628	1,06,808	12,598	15,397	18,447	4,368	5,808	7,541	27.6	36.8	47.7	13.6	21.0	31.4
Sanoofi India	2,956	3,954	Buy	715	18,374	19,476	20,450	4,913	5,446	4,981	3,468	3,944	3,596	150.8	171.5	156.3	5.5	0.7	1.8
Zota Health Care	1,300	1,679	Buy	473	5,387	9,083	13,739	185	644	1,779	(668)	(307)	624	(19.4)	(8.9)	18.1	59.7	209.8	-
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	PIE (X)			EV/EBITDA (X)			PIBV (X)			RoE (%)			RoCE (%)		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Large Cap (M-cap >US\$5bn)																			
Alkem Laboratories	5,250	5,952	Hold	6,590	25.7	26.8	23.6	20.6	17.9	15.9	4.4	3.9	3.4	18.3	15.3	15.3	15.6	13.2	13.2
Cipla India	1,330	1,615	Buy	11,277	26.3	27.0	21.4	16.7	16.6	13.4	3.1	2.9	2.6	12.4	11.1	12.7	10.3	9.3	10.8
Dr Reddy's Laboratories	1,240	1,098	Sell	10,866	24.1	31.0	23.7	16.0	18.3	14.3	2.7	2.5	2.3	11.9	11.2	12.3	7.6	5.7	7.7
Gland Pharma	3,088	2,885	Hold	5,349	48.7	36.6	28.4	29.4	25.4	21.4	4.9	4.3	3.8	10.5	12.6	14.2	8.4	10.2	10.9
Lupin	1,954	2,669	Hold	9,379	17.0	23.6	20.0	10.6	12.5	11.4	4.0	3.5	3.0	26.4	15.7	16.2	28.4	16.6	17.4
Mankind Pharma	2,372	2,864	Hold	10,286	51.2	38.3	31.4	28.2	25.0	22.1	5.9	5.1	4.4	12.5	14.6	15.3	9.8	11.6	12.9
Sun Pharmaceutical Industries	1,771	2,437	Buy	44,602	34.1	31.1	24.7	24.1	21.1	18.6	5.1	4.5	3.9	15.9	15.3	16.9	13.2	14.3	15.4
Torrent Pharmaceuticals	4,643	4,904	Hold	18,540	70.5	76.3	63.2	41.7	30.5	26.4	18.7	16.2	13.9	27.9	22.8	23.6	9.8	7.6	8.8
Zydus Lifesciences	1,133	1,274	Hold	11,860	25.6	35.0	19.6	16.3	16.4	13.8	3.9	3.5	3.1	15.9	10.5	16.7	16.9	14.4	23.1
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Ajanta Pharma	3,328	3,282	Hold	4,366	39.6	37.9	32.1	29.5	26.0	22.1	9.2	7.7	6.4	25.4	22.1	21.6	23.8	20.6	20.6
Alembic Pharmaceuticals	798	959	Buy	1,646	21.2	19.5	18.0	15.3	12.5	11.6	2.8	2.5	2.3	13.6	13.4	13.2	11.9	11.5	11.5
Natco Pharma	789	809	Sell	1,489	10.0	17.3	16.4	8.6	13.8	12.0	1.5	1.4	1.3	15.4	8.9	8.1	19.3	11.2	10.4
Pfizer India	4,054	5,212	Hold	1,947	24.4	23.6	22.1	17.1	16.0	15.1	4.4	3.9	3.5	18.0	17.7	16.9	17.6	17.3	16.6
Small Cap (M-cap <US\$1.5bn)																			
Eris Lifesciences	1,150	1,722	Buy	1,675	25.0	24.0	20.5	16.3	13.6	11.9	4.1	3.6	3.2	18.9	15.9	16.4	12.8	12.0	12.6
Indoco Remedies	227	243	Hold	220	(21.9)	17.1	19.8	21.9	13.8	9.8	2.2	2.0	1.8	(9.7)	12.3	9.7	0.8	3.9	9.0
Jubilant Pharmova	943	1,261	Buy	1,576	34.1	25.6	19.7	13.8	11.3	9.4	2.1	2.0	1.8	6.5	7.9	9.6	4.8	5.5	6.4
Sanoofi India	2,956	3,954	Buy	715	19.6	17.2	18.9	13.3	12.0	13.2	9.1	7.6	6.6	43.1	47.9	37.2	42.2	47.0	36.6
Zota Health Care	1,300	1,679	Buy	473	(67.1)	(146.0)	71.8	238.0	68.5	24.8	6.4	6.7	6.2	(14.5)	(4.5)	9.0	(7.5)	(0.5)	8.4
Multiplex																			
Rahul Kundnani (rahul.kundnani@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Small Cap (M-cap <US\$1.5bn)																			
PVR INOX	1,405	1,400	Buy	1,448	67,192	72,133	80,485	8,571	10,619	13,593	3,866	3,667	5,625	5.8	5.1	7.0	9.4	25.9	20.6
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	PIE (X)			EV/EBITDA (X)			PIBV (X)			RoE (%)			RoCE (%)		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Small Cap (M-cap <US\$1.5bn)																			
PVR INOX	1,405	1,400	Buy	1,448	244.0	276.3	201.0	16.3	13.1	10.3	1.9	1.8	1.7	5.4	4.8	7.0	4.8	6.2	8.7

Stationery																			
Rahul Kundnani (rahul.kundnani@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
DOMS Industries	2,088	2,920	Buy	1,331	23,264	28,261	34,524	4,026	4,176	6,058	2,396	2,372	3,615	39.5	39.1	59.6	21.8	22.7	22.8
Small Cap (M-cap <US\$1.5bn)																			
Flair Writing Industries	232	364	Buy	257	12,501	14,189	16,175	2,245	2,453	2,871	1,413	1,461	1,768	13.4	13.9	16.8	13.7	13.1	11.8
Linc	85	116	Buy	53	5,430	5,674	5,958	595	582	797	367	322	502	5.5	4.8	7.8	4.7	15.8	17.0
Kokuyo Camlin	74	76	Sell	78	8,060	8,584	9,442	581	550	793	248	237	360	2.5	2.4	3.6	8.2	16.9	20.6
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	PIE (X)			EV/EBITDA (X)			PIBV (X)			RoE (%)			RoCE (%)		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
DOMS Industries	2,088	2,920	Buy	1,331	52.9	53.4	35.1	31.7	30.5	21.1	10.4	8.9	7.2	20.1	16.7	21.0	22.6	19.0	23.7
Small Cap (M-cap <US\$1.5bn)																			
Flair Writing Industries	232	364	Buy	257	17.3	16.7	13.8	11.1	10.2	8.7	2.1	1.9	1.7	13.1	12.0	12.9	14.5	13.9	14.8
Linc	85	116	Buy	53	15.3	17.7	10.8	8.6	8.7	6.4	1.9	1.7	1.5	13.3	10.3	14.9	16.7	14.3	18.5
Kokuyo Camlin	74	76	Sell	78	30.0	31.4	20.7	13.2	14.0	9.7	2.3	2.2	2.0	7.9	7.1	10.0	10.3	8.8	12.5
E-Retail/E-Commerce																			
Rahul Kundnani (rahul.kundnani@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Large Cap (M-cap >US\$5bn)																			
Eternal	321	364	Buy	32,538	5,43,640	10,22,529	14,35,531	12,080	39,613	65,120	3,660	22,412	39,672	0.4	2.3	4.1	62.5	132.2	229.2
Swiggy	232	355	Buy	6,735	2,30,530	2,76,924	3,38,698	(32,310)	(8,526)	9,770	(41,540)	(17,150)	(2,658)	(15.0)	(6.2)	(0.9)	21.2	-	(74.7)
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	PIE (X)			PIS (X)			PIBV (X)			RoE (%)			RoCE (%)		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Large Cap (M-cap >US\$5bn)																			
Eternal	321	364	Buy	32,538	846.4	138.2	78.1	5.7	3.1	2.2	10.0	8.6	7.3	1.2	6.2	9.3	(0.7)	4.2	7.4
Swiggy	232	355	Buy	6,735	(15.5)	(37.5)	(247.1)	2.8	2.3	1.9	3.5	3.7	3.6	(22.7)	(10.0)	(1.5)	(21.3)	(10.7)	(2.6)
Flex Workspace																			
Rahul Kundnani (rahul.kundnani@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Small Cap (M-cap <US\$1.5bn)																			
Wework India Management	677	983	Buy	987	24,402	30,172	36,719	4,772	6,031	7,518	792	1,218	1,886	6	9	14	22.7	25.5	54.3
Smartworks Coworking Spaces	480	630	Buy	576	17,958	22,982	29,112	3,144	4,438	5,677	105	957	2,914	0.9	8.4	25.5	27.3	34.4	426.1
Indiube Spaces	188	235	Buy	418	14,508	18,960	23,783	2,533	3,396	4,448	(1,063)	(961)	549	(5.0)	(4.5)	2.6	28.0	32.5	-
Awfs Space Solutions	251	364	Buy	188	14,940	18,385	22,615	2,130	2,821	3,560	713	1,314	1,834	10.0	18.4	25.6	23.0	29.3	60.3
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	PIE (X)			EV/EBITDA (X)			PIBV (X)			RoE (%)			RoCE (%)		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Small Cap (M-cap <US\$1.5bn)																			
Wework India Management	677	983	Buy	987	115.7	75.2	48.6	20.3	16.0	12.9	2.3	1.6	1.1	30.8	34.5	37.1	38.3	41.1	43.4
Smartworks Coworking Spaces	480	630	Buy	576	521.0	57.3	18.8	17.4	12.3	9.6	10.3	8.8	6.0	3.3	16.5	37.7	19.0	26.4	28.7
Indiube Spaces	188	235	Buy	418	(37.5)	(41.5)	72.6	15.4	11.5	8.7	7.7	9.5	8.4	(41.6)	(20.6)	12.3	17.3	24.0	26.0
Awfs Space Solutions	251	364	Buy	188	25.1	13.6	9.8	8.2	6.2	4.9	3.2	2.6	2.1	14.1	21.3	23.6	15.2	25.2	26.2
Retail																			
Rahul Kundnani (rahul.kundnani@nirmalbang.com)																			
Operational Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	Net sales (Rsmn)			EBITDA (Rsmn)			PAT (Rsmn)			EPS (Rs)			CAGR FY26-FY28E		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	Sales	EBITDA	PAT
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Bata India	615	772	Hold	830	35,155	37,699	41,469	7,065	7,646	8,737	1,659	2,155	2,827	12.9	16.8	22.0	8.6	11.2	30.5
Small Cap (M-cap <US\$1.5bn)																			
V-Mart Retail	820	830	Buy	685	37,894	45,584	53,419	5,135	6,305	8,053	1,240	1,398	1,586	15.6	17.6	20.0	18.7	25.2	13.1
Valuation Metrics																			
Company	CMP (Rs)	TP (Rs)	Current Rating	M-cap (US\$mn)	PIE (X)			EV/EBITDA (X)			PIBV (X)			RoE (%)			RoCE (%)		
					FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
Mid Cap (M-cap between US\$1.5bn to 5bn)																			
Bata India	615	772	Hold	830	47.7	36.7	28.0	11.9	11.0	9.7	5.0	5.0	4.9	10.5	13.6	17.7	8.0	9.5	12.4
Small Cap (M-cap <US\$1.5bn)																			
V-Mart Retail	820	830	Buy	685	52.5	46.6	41.1	14.5	11.8	9.3	6.8	5.9	5.2	14.1	13.7	13.5	17.2	16.4	17.0

DISCLOSURES

This Report is published by Nirmal Bang Equities Private Limited (hereinafter referred to as "NBEPL") for private circulation. NBEPL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 2014 having Registration no. INH000001436. NBEPL is also a registered Stock Broker with National Stock Exchange of India Limited and BSE Limited in cash and derivatives segments.

NBEPL has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets.

NBEPL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. NBEPL, its associates or analyst or his relatives do not hold any financial interest in the subject company. NBEPL or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. NBEPL or its associates or Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report.

NBEPL or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. NBEPL or its associates have not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of Subject Company and NBEPL / analyst has not been engaged in market making activity of the subject company.

Analyst Certification: I/We, Vinod Rajamani, NBIE research analyst and Jay Betai Research Associate, the author of this report, hereby certify that the views expressed in this research report accurately reflects my/our personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst(s) principally responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

Disclaimer

Stock Ratings Absolute Returns

BUY > 15%

HOLD -5% to 14%

SELL < -5%

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. NBEPL is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader.

This research has been prepared for the general use of the clients of NBEPL and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NBEPL will not treat recipients as customers by virtue of their receiving this report. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NBEPL & its group companies to registration or licensing requirements within such jurisdictions.

The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. NBEPL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NBEPL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

This information is subject to change without any prior notice. NBEPL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, NBEPL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.

Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of NBEPL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Here it may be noted that neither NBEPL, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in this report.

Copyright of this document vests exclusively with NBEPL.

**Registration granted by SEBI and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors."

Our reports are also available on our website www.nirmalbang.com

Access all our reports on Bloomberg, Thomson Reuters and Factset.

Team Details:

Name	Email Id	Direct Line
Anand Gulani	CEO & Head of Equities	anand.gulani@nirmalbang.com
		+91 22 6273 8098/99

Research Team Details:

Research Analyst	Designation	Sector	Email Id	Direct Line
Teresa John	Head of Research & Economist	Economy & Strategy	teresa.john@nirmalbang.com	022 6273 8114
Abhishek Navalgund	Deputy Head of Research & Research Analyst	Chemicals, Hotels & Mid-caps	abhishek.nalgund@nirmalbang.com	022 6273 8089
Akshat Agrawal	Research Analyst	BFSI	akshat.agrawal@nirmalbang.com	022 6273 8210
Vinod Rajamani	Research Analyst	Insurance and NBFC	vinod.rajamani@nirmalbang.com	022 6273 8033
Yash Agrawal	Research Analyst	Auto - OEM, Auto - Ancillary	yash.agrawal@nirmalbang.com	022 6273 8017
Niharika Agarwal	Research Analyst	Pharma	niharika.agarwal@nirmalbang.com	
Rahul Kundnani	Research Analyst	Midcaps, Stationery	rahul.kundnani@nirmalbang.com	022 6273 8174
Girija Shankar Ray	Research Analyst	Cement	girijashankar.ray@nirmalbang.com	022 6273 8171
Rabindra Nath Nayak	Research Analyst	Consumer Durables & Capital Goods	rabindranath.nayak@nirmalbang.com	022 62738092
Yash Nandwani	Research Analyst	Oil & Gas and Mid-caps	Yash.nandwani@nirmalbang.com	022 62738065
Shibangi Choudhury	Research Analyst	Midcaps	shibangi.choudhury@nirmalbang.com	022 6273 8145
Vaibhav Vidwani	Lead Associate	Housing Finance	vaibhav.vidwani@nirmalbang.com	022 6273 8176

Dealing

Vijay Singh Gussain	Head of Dealing & Sales trading	vijaysingh.gussain@nirmalbang.com	-
Michael Pillai	Dealing Desk	michael.pillai@nirmalbang.com	+91 22 6273 8102/03, +91 22 6636 8830

Nirmal Bang Equities Pvt. Ltd.

Correspondence Address

B-2, 301/302, Marathon Innova, Nr. Peninsula Corporate Park, Lower Parel (W), Mumbai-400013.

Board No. : 91 22 6273 8000/1; Fax. : 022 6273 8010